{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["anti-inflammatory", "antioxidant", "pharmacological interventions", "pro-apoptotic", "silybin", "silymarin"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "36014565", "DateCompleted": {"Year": "2022", "Month": "08", "Day": "29"}, "DateRevised": {"Year": "2023", "Month": "12", "Day": "13"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "08", "Day": "21"}], "Language": ["eng"], "ELocationID": ["5327", "10.3390/molecules27165327"], "Journal": {"ISSN": "1420-3049", "JournalIssue": {"Volume": "27", "Issue": "16", "PubDate": {"Year": "2022", "Month": "Aug", "Day": "21"}}, "Title": "Molecules (Basel, Switzerland)", "ISOAbbreviation": "Molecules"}, "ArticleTitle": "Mechanistic Insights into the Pharmacological Significance of Silymarin.", "Abstract": {"AbstractText": ["Medicinal plants are considered the reservoir of diverse therapeutic agents and have been traditionally employed worldwide to heal various ailments for several decades. Silymarin is a plant-derived mixture of polyphenolic flavonoids originating from the fruits and akenes of <i>Silybum marianum</i> and contains three flavonolignans, silibinins (silybins), silychristin and silydianin, along with taxifolin. Silybins are the major constituents in silymarin with almost 70-80% abundance and are accountable for most of the observed therapeutic activity. Silymarin has also been acknowledged from the ancient period and is utilized in European and Asian systems of traditional medicine for treating various liver disorders. The contemporary literature reveals that silymarin is employed significantly as a neuroprotective, hepatoprotective, cardioprotective, antioxidant, anti-cancer, anti-diabetic, anti-viral, anti-hypertensive, immunomodulator, anti-inflammatory, photoprotective and detoxification agent by targeting various cellular and molecular pathways, including MAPK, mTOR, \u03b2-catenin and Akt, different receptors and growth factors, as well as inhibiting numerous enzymes and the gene expression of several apoptotic proteins and inflammatory cytokines. Therefore, the current review aims to recapitulate and update the existing knowledge regarding the pharmacological potential of silymarin as evidenced by vast cellular, animal, and clinical studies, with a particular emphasis on its mechanisms of action."]}, "AuthorList": [{"Identifier": ["0000-0002-0524-1714"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak 124001, Haryana, India."}], "LastName": "Wadhwa", "ForeName": "Karan", "Initials": "K"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Pharmaceutical Sciences, Kurukshetra University, Kurukshetra 136119, Haryana, India."}], "LastName": "Pahwa", "ForeName": "Rakesh", "Initials": "R"}, {"Identifier": ["0000-0003-2042-1243"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "M.M. College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Ambala 133207, Haryana, India."}], "LastName": "Kumar", "ForeName": "Manish", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Technology, Meerut Institute of Engineering and Technology (MIET), Meerut 250005, Uttar Pradesh, India."}], "LastName": "Kumar", "ForeName": "Shobhit", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Chemistry, Delhi Pharmaceutical Sciences and Research University, New Delhi 110017, Delhi, India."}], "LastName": "Sharma", "ForeName": "Prabodh Chander", "Initials": "PC"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak 124001, Haryana, India."}], "LastName": "Singh", "ForeName": "Govind", "Initials": "G"}, {"Identifier": ["0000-0003-3397-703X"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacy, G.D. Goenka University, Sohna Road, Gurugram 122103, Haryana, India."}], "LastName": "Verma", "ForeName": "Ravinder", "Initials": "R"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak 124001, Haryana, India."}], "LastName": "Mittal", "ForeName": "Vineet", "Initials": "V"}, {"Identifier": ["0000-0002-1860-4246"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Chitkara College of Pharmacy, Chitkara University, Rajpura 140401, Punjab, India."}], "LastName": "Singh", "ForeName": "Inderbir", "Initials": "I"}, {"Identifier": ["0000-0002-3286-196X"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak 124001, Haryana, India."}], "LastName": "Kaushik", "ForeName": "Deepak", "Initials": "D"}, {"Identifier": ["0000-0003-3023-4871"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Research Unit-Induced Resistance and Plant Bioprotection, University of Reims, EA 4707-USC INRAe 1488, SFR Condorcet FR CNRS 3417, 51687 Reims, France."}], "LastName": "Jeandet", "ForeName": "Philippe", "Initials": "P"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Molecules", "NlmUniqueID": "100964009", "ISSNLinking": "1420-3049"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antioxidants"}, {"RegistryNumber": "0", "NameOfSubstance": "Flavonoids"}, {"RegistryNumber": "0", "NameOfSubstance": "Silymarin"}], "MeshHeadingList": [{"QualifierName": ["metabolism", "pharmacology", "therapeutic use"], "DescriptorName": "Antioxidants"}, {"QualifierName": ["metabolism"], "DescriptorName": "Flavonoids"}, {"QualifierName": [], "DescriptorName": "Fruit"}, {"QualifierName": ["metabolism"], "DescriptorName": "Silybum marianum"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Silymarin"}], "CoiStatement": "The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Nikam P.H., Kareparamban J., Jadhav A., Kadam V. Future Trends in Standardization of Herbal Drugs. J. Appl. Pharm. Sci. 2012;2:38\u201344. doi: 10.7324/JAPS.2012.2631.", "ArticleIdList": ["10.7324/JAPS.2012.2631"]}, {"Citation": "Saller R., Melzer J., Reichling J., Brignoli R., Meier R. An Updated Systematic Review of the Pharmacology of Silymarin. Forsch. Komplement. 2007;14:70\u201380. doi: 10.1159/000100581.", "ArticleIdList": ["10.1159/000100581", "17464157"]}, {"Citation": "Bhattacharya S. Phytotherapeutic Properties of Milk Thistle Seeds: An Overview. J. Adv. Pharm. Educ. Res. 2011;1:69\u201379."}, {"Citation": "Das S.K., Mukherjee S., Vasudevan D.M. Medicinal Properties of Milk Thistle with Special Reference to Silymarin An Overview. Nat. Prod. Radiance. 2008;7:182\u2013192."}, {"Citation": "Ghosh A., Ghosh T., Jain S. Silymarin\u2014A Review on the Pharmacodynamics and Bioavailability Enhancement Approaches. J. Pharm. Sci. Technol. 2010;2:348\u2013355."}, {"Citation": "Schuppan D., Jia J.I.D., Brinkhaus B., Hahn E.G. Herbal Products for Liver Diseases: A Therapeutic Challenge for the New Millennium. Hepatology. 1999;30:1099\u20131104. doi: 10.1002/hep.510300437.", "ArticleIdList": ["10.1002/hep.510300437", "10498665"]}, {"Citation": "Ramasamy K., Agarwal R. Multitargeted Therapy of Cancer by Silymarin. Cancer Lett. 2008;269:352\u2013362. doi: 10.1016/j.canlet.2008.03.053.", "ArticleIdList": ["10.1016/j.canlet.2008.03.053", "PMC2612997", "18472213"]}, {"Citation": "Sharma A., Puri V., Kakkar V., Singh I. Formulation and Evaluation of Silymarin-Loaded Chitosan-Montmorilloite Microbeads for the Potential Treatment of Gastric Ulcers. J. Funct. Biomater. 2018;9:52. doi: 10.3390/jfb9030052.", "ArticleIdList": ["10.3390/jfb9030052", "PMC6164251", "30201932"]}, {"Citation": "Chang L.W., Hou M.L., Tsai T.H. Silymarin in Liposomes and Ethosomes: Pharmacokinetics and Tissue Distribution in Free-Moving Rats by High-Performance Liquid Chromatography-Tandem Mass Spectrometry. J. Agric. Food Chem. 2014;62:11657\u201311665. doi: 10.1021/jf504139g.", "ArticleIdList": ["10.1021/jf504139g", "25375210"]}, {"Citation": "Flora K., Hahn M., Rosen H., Benner K. Milk Thistle (Silybum marianum) for the Therapy of Liver Disease. Am. J. Gastroenterol. 1998;93:139\u2013143. doi: 10.1111/j.1572-0241.1998.00139.x.", "ArticleIdList": ["10.1111/j.1572-0241.1998.00139.x", "9468229"]}, {"Citation": "Gazak R., Walterova D., Kren V. Silybin and Silymarin-New and Emerging Applications in Medicine. Curr. Med. Chem. 2007;14:315\u2013338. doi: 10.2174/092986707779941159.", "ArticleIdList": ["10.2174/092986707779941159", "17305535"]}, {"Citation": "Neha, Jaggi A., Singh N. Advances in Experimental Medicine and Biology. Volume 929. Springer; Berlin/Hamburg, Germany: 2016. Silymarin and Its Role in Chronic Diseases; pp. 25\u201344.", "ArticleIdList": ["27771919"]}, {"Citation": "Palit P., Mukhopadhyay A., Chattopadhyay D. Phyto-Pharmacological Perspective of Silymarin: A Potential Prophylactic or Therapeutic Agent for COVID-19, Based on Its Promising Immunomodulatory, Anti-Coagulant and Anti-Viral Property. Phyther. Res. 2021;35:4246\u20134257. doi: 10.1002/ptr.7084.", "ArticleIdList": ["10.1002/ptr.7084", "PMC8250558", "33817867"]}, {"Citation": "Abenavoli L., Izzo A.A., Mili\u0107 N., Cicala C., Santini A., Capasso R. Milk Thistle (Silybum marianum): A Concise Overview on Its Chemistry, Pharmacological, and Nutraceutical Uses in Liver Diseases. Phyther. Res. 2018;32:2202\u20132213. doi: 10.1002/ptr.6171.", "ArticleIdList": ["10.1002/ptr.6171", "30080294"]}, {"Citation": "Lv Y., Gao S., Xu S., Du G., Zhou J., Chen J. Spatial Organization of Silybin Biosynthesis in Milk Thistle [Silybum marianum (L.) Gaertn] Plant J. 2017;92:995\u20131004. doi: 10.1111/tpj.13736.", "ArticleIdList": ["10.1111/tpj.13736", "28990236"]}, {"Citation": "Bijak M. Silybin, a Major Bioactive Component of Milk Thistle (Silybum marianum L. Gaernt.)\u2014Chemistry, Bioavailability, and Metabolism. Molecules. 2017;22:1942. doi: 10.3390/molecules22111942.", "ArticleIdList": ["10.3390/molecules22111942", "PMC6150307", "29125572"]}, {"Citation": "Dixit N., Baboota S., Kohli K., Ahmad S., Ali J. Silymarin: A Review of Pharmacological Aspects and Bioavailability Enhancement Approaches. Indian J. Pharmacol. 2007;39:172\u2013179. doi: 10.4103/0253-7613.36534.", "ArticleIdList": ["10.4103/0253-7613.36534"]}, {"Citation": "Elwekeel A., Elfishawy A., Abouzid S. Silymarin Content in Silybum marianum Fruits at Different Maturity Stages. J. Med. Plants Res. 2013;7:1665\u20131669. doi: 10.5897/JMPR12.0743.", "ArticleIdList": ["10.5897/JMPR12.0743"]}, {"Citation": "Javed S., Kohli K., Ali M. Reassessing Bioavailability of Silymarin. Altern. Med. Rev. 2011;16:239\u2013249.", "ArticleIdList": ["21951025"]}, {"Citation": "Reddy K.R. Silymarin for the treatment of chronic liver disease. Gastroenterol. Hepatol. (N. Y.) 2007;3:825\u2013826.", "ArticleIdList": ["PMC3104142", "21960792"]}, {"Citation": "Kaur M., Agarwal R. Silymarin and Epithelial Cancer Chemoprevention: How Close We Are to Bedside? Toxicol. Appl. Pharmacol. 2007;224:350\u2013359. doi: 10.1016/j.taap.2006.11.011.", "ArticleIdList": ["10.1016/j.taap.2006.11.011", "PMC2692696", "17184801"]}, {"Citation": "Javed S., Ahsan W., Kohli K. Pharmacological Influences of Natural Products as Bioenhancers of Silymarin against Carbon Tetrachloride-Induced Hepatotoxicity in Rats. Clin. Phytoscience. 2018;4:18. doi: 10.1186/s40816-018-0079-6.", "ArticleIdList": ["10.1186/s40816-018-0079-6"]}, {"Citation": "Home-Nano Silymarin OIC NEW: Nano Silymarin OIC NEW.  [(accessed on 5 July 2022)].  Available online:  https://nanosilymarin.vn/en/"}, {"Citation": "Zhang Z., Li X., Sang S., McClements D.J., Chen L., Long J., Jiao A., Wang J., Jin Z., Qiu C. A Review of Nanostructured Delivery Systems for the Encapsulation, Protection, and Delivery of Silymarin: An Emerging Nutraceutical. Food. Res. Int. 2022;156:111314. doi: 10.1016/j.foodres.2022.111314.", "ArticleIdList": ["10.1016/j.foodres.2022.111314", "35651070"]}, {"Citation": "Wadhwa K., Kadian V., Puri V., Bhardwaj B.Y., Sharma A., Pahwa R., Rao R., Gupta M., Singh I. New Insights into Quercetin Nanoformulations for Topical Delivery. Phytomedicine Plus. 2022;2:100257. doi: 10.1016/j.phyplu.2022.100257.", "ArticleIdList": ["10.1016/j.phyplu.2022.100257"]}, {"Citation": "Saini V., Singh A., Shukla R., Jain K., Yadav A.K. Silymarin-Encapsulated Xanthan Gum\u2013Stabilized Selenium Nanocarriers for Enhanced Activity against Amyloid Fibril Cytotoxicity. AAPS PharmSciTech. 2022;23:125. doi: 10.1208/s12249-022-02274-0.", "ArticleIdList": ["10.1208/s12249-022-02274-0", "35474400"]}, {"Citation": "Elfaky M.A., Sirwi A., Ismail S.H., Awad H.H., Gad S.S. Hepatoprotective Effect of Silver Nanoparticles at Two Different Particle Sizes: Comparative Study with and without Silymarin. Curr. Issues Mol. Biol. 2022;44:2923\u20132938. doi: 10.3390/cimb44070202.", "ArticleIdList": ["10.3390/cimb44070202", "PMC9321183", "35877426"]}, {"Citation": "Abdullah A.S., El Sayed I.E.T., El-Torgoman A.M.A., Kalam A., Wageh S., Kamel M.A. Green Synthesis of Silymarin\u2013Chitosan Nanoparticles as a New Nano Formulation with Enhanced Anti-Fibrotic Effects against Liver Fibrosis. Int. J. Mol. Sci. 2022;23:5420. doi: 10.3390/ijms23105420.", "ArticleIdList": ["10.3390/ijms23105420", "PMC9141191", "35628233"]}, {"Citation": "Patel P., Raval M., Manvar A., Airao V., Bhatt V., Shah P. Lung Cancer Targeting Efficiency of Silibinin Loaded Poly Caprolactone/Pluronic F68 Inhalable Nanoparticles: In Vitro and In Vivo Study. PLoS ONE. 2022;17:e0267257. doi: 10.1371/journal.pone.0267257.", "ArticleIdList": ["10.1371/journal.pone.0267257", "PMC9106168", "35560136"]}, {"Citation": "Iqbal J., Andleeb A., Ashraf H., Meer B., Mehmood A., Jan H., Zaman G., Nadeem M., Drouet S., Fazal H., et al. Potential Antimicrobial, Antidiabetic, Catalytic, Antioxidant and ROS/RNS Inhibitory Activities of Silybum marianum Mediated Biosynthesized Copper Oxide Nanoparticles. RSC Adv. 2022;12:14069\u201314083. doi: 10.1039/D2RA01929A.", "ArticleIdList": ["10.1039/D2RA01929A", "PMC9094097", "35558860"]}, {"Citation": "Staroverov S.A., Kozlov S.V., Fomin A.S., Gabalov K.P., Khanadeev V.A., Soldatov D.A., Domnitsky I.Y., Dykman L.A., Akchurin S.V., Guliy O.I. Synthesis of Silymarin\u2212selenium Nanoparticle Conjugate and Examination of Its Biological Activity in Vitro. ADMET DMPK. 2021;9:255\u2013266. doi: 10.5599/admet.1023.", "ArticleIdList": ["10.5599/admet.1023", "PMC8920099", "35300372"]}, {"Citation": "Silymarin|Side Effects|Dosage|Precautions|Medicine.  [(accessed on 5 July 2022)].  Available online:  https://www.medicoverhospitals.in/medicine/silymarin."}, {"Citation": "Han Y., Guo D., Chen Y., Chen Y., Tan Z.R., Zhou H.H. Effect of Silymarin on the Pharmacokinetics of Losartan and Its Active Metabolite E-3174 in Healthy Chinese Volunteers. Eur. J. Clin. Pharmacol. 2009;65:585\u2013591. doi: 10.1007/s00228-009-0624-9.", "ArticleIdList": ["10.1007/s00228-009-0624-9", "19221727"]}, {"Citation": "Molt\u00f3 J., Valle M., Miranda C., Cede\u00f1o S., Negredo E., Clotet B. Effect of Milk Thistle on the Pharmacokinetics of Darunavir-Ritonavir in HIV-Infected Patients. Antimicrob. Agents Chemother. 2012;56:2837\u20132841. doi: 10.1128/AAC.00025-12.", "ArticleIdList": ["10.1128/AAC.00025-12", "PMC3370734", "22430963"]}, {"Citation": "Almazroo O.A., Miah M.K., Venkataramanan R. Drug Metabolism in the Liver. Clin. Liver Dis. 2017;21:1\u201320. doi: 10.1016/j.cld.2016.08.001.", "ArticleIdList": ["10.1016/j.cld.2016.08.001", "27842765"]}, {"Citation": "Derosa G., Bonaventura A., Bianchi L., Romano D., D\u2019angelo A., Fogari E., Maffioli P. Berberis Aristata/Silybum marianum Fixed Combination on Lipid Profile and Insulin Secretion in Dyslipidemic Patients. Expert Opin. Biol. Ther. 2013;13:1495\u20131506. doi: 10.1517/14712598.2013.832751.", "ArticleIdList": ["10.1517/14712598.2013.832751", "23971720"]}, {"Citation": "Derosa G., Romano D., D\u2019Angelo A., Maffioli P. Berberis Aristata Combined with Silybum marianum on Lipid Profile in Patients Not Tolerating Statins at High Doses. Atherosclerosis. 2015;239:87\u201392. doi: 10.1016/j.atherosclerosis.2014.12.043.", "ArticleIdList": ["10.1016/j.atherosclerosis.2014.12.043", "25577665"]}, {"Citation": "Derosa G., D\u2019Angelo A., Romano D., Maffioli P. Effects of a Combination of Berberis Aristata, Silybum marianum and Monacolin on Lipid Profile in Subjects at Low Cardiovascular Risk; A Double-Blind, Randomized, Placebo-Controlled Trial. Int. J. Mol. Sci. 2017;18:343. doi: 10.3390/ijms18020343.", "ArticleIdList": ["10.3390/ijms18020343", "PMC5343878", "28178209"]}, {"Citation": "Mengesha T., Sekaran N.G., Mehare T. Hepatoprotective Effect of Silymarin on Fructose Induced Nonalcoholic Fatty Liver Disease in Male Albino Wistar Rats. BMC Complement. Med. Ther. 2021;21:104. doi: 10.1186/s12906-021-03275-5.", "ArticleIdList": ["10.1186/s12906-021-03275-5", "PMC8011178", "33785007"]}, {"Citation": "Abdel-Moneim A.M., Al-Kahtani M.A., El-Kersh M.A., Al-Omair M.A. Free Radical-Scavenging, Anti-Inflammatory/Anti-Fibrotic and Hepatoprotective Actions of Taurine and Silymarin against CCl4 Induced Rat Liver Damage. PLoS ONE. 2015;10:e0144509. doi: 10.1371/journal.pone.0144509.", "ArticleIdList": ["10.1371/journal.pone.0144509", "PMC4676695", "26659465"]}, {"Citation": "Tsai J.H., Liu J.Y., Wu T.T., Ho P.C., Huang C.Y., Shyu J.C., Hsieh Y.S., Tsai C.C., Liu Y.C. Effects of Silymarin on the Resolution of Liver Fibrosis Induced by Carbon Tetrachloride in Rats. J. Viral Hepat. 2008;15:508\u2013514. doi: 10.1111/j.1365-2893.2008.00971.x.", "ArticleIdList": ["10.1111/j.1365-2893.2008.00971.x", "18397225"]}, {"Citation": "Sokar S.S., El-Sayad M.E.S., Ghoneim M.E.S., Shebl A.M. Combination of Sitagliptin and Silymarin Ameliorates Liver Fibrosis Induced by Carbon Tetrachloride in Rats. Biomed. Pharmacother. 2017;89:98\u2013107. doi: 10.1016/j.biopha.2017.02.010.", "ArticleIdList": ["10.1016/j.biopha.2017.02.010", "28222401"]}, {"Citation": "Keshavarz-Maleki R., Shalmani A.A., Gholami M., Sabzevari S., Rahimzadegan M., Jeivad F., Sabzevari O. The Ameliorative Effect of Monomethyl Fumarate and Silymarin against Valproic Acid Induced Hepatotoxicity in Rats. Pharm. Chem. J. 2021;55:240\u2013245. doi: 10.1007/s11094-021-02405-0.", "ArticleIdList": ["10.1007/s11094-021-02405-0"]}, {"Citation": "Chen I.S., Chen Y.C., Chou C.H., Chuang R.F., Sheen L.Y., Chiu C.H. Hepatoprotection of Silymarin against Thioacetamide-Induced Chronic Liver Fibrosis. J. Sci. Food Agric. 2012;92:1441\u20131447. doi: 10.1002/jsfa.4723.", "ArticleIdList": ["10.1002/jsfa.4723", "22102319"]}, {"Citation": "Heidarian E., Nouri A. Hepatoprotective Effects of Silymarin against Diclofenac-Induced Liver Toxicity in Male Rats Based on Biochemical Parameters and Histological Study. Arch. Physiol. Biochem. 2021;127:112\u2013118. doi: 10.1080/13813455.2019.1620785.", "ArticleIdList": ["10.1080/13813455.2019.1620785", "31165636"]}, {"Citation": "Mahli A., Koch A., Czech B., Peterburs P., Lechner A., Haunschild J., M\u00fcller M., Hellerbrand C. Hepatoprotective Effect of Oral Application of a Silymarin Extract in Carbon Tetrachloride-Induced Hepatotoxicity in Rats. Clin. Phytoscience. 2015;1:5. doi: 10.1186/s40816-015-0006-z.", "ArticleIdList": ["10.1186/s40816-015-0006-z"]}, {"Citation": "Shaker E., Mahmoud H., Mnaa S. Silymarin, the Antioxidant Component and Silybum marianum Extracts Prevent Liver Damage. Food Chem. Toxicol. 2010;48:803\u2013806. doi: 10.1016/j.fct.2009.12.011.", "ArticleIdList": ["10.1016/j.fct.2009.12.011", "20034535"]}, {"Citation": "Freitag A.F., Cardia G.F.E., Da Rocha B.A., Aguiar R.P., Silva-Comar F.M.D.S., Spironello R.A., Grespan R., Caparroz-Assef S.M., Bersani-Amado C.A., Cuman R.K.N. Hepatoprotective Effect of Silymarin (Silybum marianum) on Hepatotoxicity Induced by Acetaminophen in Spontaneously Hypertensive Rats. Evid.-Based Complement. Altern. Med. 2015;2015:1\u20138. doi: 10.1155/2015/538317.", "ArticleIdList": ["10.1155/2015/538317", "PMC4363982", "25821491"]}, {"Citation": "Haddad P.S., Haddad Y., Vallerand D., Brault A. Antioxidant and Hepatoprotective Effects of Silibinin in a Rat Model of Nonalcoholic Steatohepatitis. Evid.-Based Complement. Altern. Med. 2011;2011:1\u201310. doi: 10.1093/ecam/nep164.", "ArticleIdList": ["10.1093/ecam/nep164", "PMC3136786", "19884114"]}, {"Citation": "Zhu S.Y., Jiang N., Yang J., Tu J., Zhou Y., Xiao X., Dong Y. Silybum marianum Oil Attenuates Hepatic Steatosis and Oxidative Stress in High Fat Diet-Fed Mice. Biomed. Pharmacother. 2018;100:191\u2013197. doi: 10.1016/j.biopha.2018.01.144.", "ArticleIdList": ["10.1016/j.biopha.2018.01.144", "29428667"]}, {"Citation": "Ou Q., Weng Y., Wang S., Zhao Y., Zhang F., Zhou J., Wu X. Silybin Alleviates Hepatic Steatosis and Fibrosis in NASH Mice by Inhibiting Oxidative Stress and Involvement with the NF-\u03baB Pathway. Dig. Dis. Sci. 2018;63:3398\u20133408. doi: 10.1007/s10620-018-5268-0.", "ArticleIdList": ["10.1007/s10620-018-5268-0", "30191499"]}, {"Citation": "Aghazadeh S., Amini R., Yazdanparast R., Ghaffari S.H. Anti-Apoptotic and Anti-Inflammatory Effects of Silybum marianum in Treatment of Experimental Steatohepatitis. Exp. Toxicol. Pathol. 2011;63:569\u2013574. doi: 10.1016/j.etp.2010.04.009.", "ArticleIdList": ["10.1016/j.etp.2010.04.009", "20471811"]}, {"Citation": "Kim S.H., Oh D.S., Oh J.Y., Son T.G., Yuk D.Y., Jung Y.S. Silymarin Prevents Restraint Stress-Induced Acute Liver Injury by Ameliorating Oxidative Stress and Reducing Inflammatory Response. Molecules. 2016;21:443. doi: 10.3390/molecules21040443.", "ArticleIdList": ["10.3390/molecules21040443", "PMC6274117", "27043523"]}, {"Citation": "Zhang B., Xu D., She L., Wang Z., Yang N., Sun R., Zhang Y., Yan C., Wei Q., Aa J., et al. Silybin Inhibits NLRP3 Inflammasome Assembly through the NAD+/SIRT2 Pathway in Mice with Nonalcoholic Fatty Liver Disease. FASEB J. 2018;32:757\u2013767. doi: 10.1096/fj.201700602R.", "ArticleIdList": ["10.1096/fj.201700602R", "28970254"]}, {"Citation": "Alaca N., \u00d6zbeyli D., Uslu S., \u015eahin H.H., Yi\u01e7itt\u00f6rk G., Kurtel H., \u00d6ktem G., Ye\u01e7en B.\u00c7. Treatment with Milk Thistle Extract (Silybum marianum), Ursodeoxycholic Acid, or Their Combination Attenuates Cholestatic Liver Injury in Rats: Role of the Hepatic Stem Cells. Turkish J. Gastroenterol. 2017;28:476\u2013484. doi: 10.5152/tjg.2017.16742.", "ArticleIdList": ["10.5152/tjg.2017.16742", "29086715"]}, {"Citation": "Fried M.W., Navarro V.J., Afdhal N., Belle S.H., Wahed A.S., Hawke R.L., Doo E., Meyers C.M., Reddy K.R. Effect of Silymarin (Milk Thistle) on Liver Disease in Patients with Chronic Hepatitis C Unsuccessfully Treated with Interferon Therapy: A Randomized Controlled Trial. JAMA-J. Am. Med. Assoc. 2012;308:274\u2013282. doi: 10.1001/jama.2012.8265.", "ArticleIdList": ["10.1001/jama.2012.8265", "PMC3683986", "22797645"]}, {"Citation": "Clichici S., Olteanu D., Nagy A.L., Oros A., Filip A., Mircea P.A. Silymarin Inhibits the Progression of Fibrosis in the Early Stages of Liver Injury in CCl4-Treated Rats. J. Med. Food. 2015;18:290\u2013298. doi: 10.1089/jmf.2013.0179.", "ArticleIdList": ["10.1089/jmf.2013.0179", "25133972"]}, {"Citation": "Raghu R., Karthikeyan S. Zidovudine and Isoniazid Induced Liver Toxicity and Oxidative Stress: Evaluation of Mitigating Properties of Silibinin. Environ. Toxicol. Pharmacol. 2016;46:217\u2013226. doi: 10.1016/j.etap.2016.07.014.", "ArticleIdList": ["10.1016/j.etap.2016.07.014", "27497728"]}, {"Citation": "Malaguarnera M., Di Rosa M., Nicoletti F., Malaguarnera L. Molecular Mechanisms Involved in NAFLD Progression. J. Mol. Med. 2009;87:679\u2013695. doi: 10.1007/s00109-009-0464-1.", "ArticleIdList": ["10.1007/s00109-009-0464-1", "19352614"]}, {"Citation": "Shaarawy S.M., Tohamy A.A., Elgendy S.M., Abd Elmageed Z.Y., Bahnasy A., Mohamed M.S., Kandil E., Matrougui K. Protective Effects of Garlic and Silymarin on NDEA-Induced Rats Hepatotoxicity. Int. J. Biol. Sci. 2009;5:549\u2013557. doi: 10.7150/ijbs.5.549.", "ArticleIdList": ["10.7150/ijbs.5.549", "PMC2737715", "19742242"]}, {"Citation": "Federico A., Dallio M., Masarone M., Gravina A.G., Di Sarno R., Tuccillo C., Cossiga V., Lama S., Stiuso P., Morisco F., et al. Evaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters, and Serological Worsening Markers in Nonalcoholic Fatty Liver Disease Patients. Oxid. Med. Cell. Longev. 2019;2019:1\u201312. doi: 10.1155/2019/8742075.", "ArticleIdList": ["10.1155/2019/8742075", "PMC6815609", "31737175"]}, {"Citation": "Gharagozloo M., Jafari S., Esmaeil N., Javid E.N., Bagherpour B., Rezaei A. Immunosuppressive Effect of Silymarin on Mitogen-Activated Protein Kinase Signalling Pathway: The Impact on T Cell Proliferation and Cytokine Production. Basic Clin. Pharmacol. Toxicol. 2013;113:209\u2013214. doi: 10.1111/bcpt.12088.", "ArticleIdList": ["10.1111/bcpt.12088", "23701595"]}, {"Citation": "Sinha K., Das J., Pal P.B., Sil P.C. Oxidative Stress: The Mitochondria-Dependent and Mitochondria-Independent Pathways of Apoptosis. Arch. Toxicol. 2013;87:1157\u20131180. doi: 10.1007/s00204-013-1034-4.", "ArticleIdList": ["10.1007/s00204-013-1034-4", "23543009"]}, {"Citation": "Kisseleva T., Brenner D. Molecular and Cellular Mechanisms of Liver Fibrosis and Its Regression. Nat. Rev. Gastroenterol. Hepatol. 2020;18:151\u2013166. doi: 10.1038/s41575-020-00372-7.", "ArticleIdList": ["10.1038/s41575-020-00372-7", "33128017"]}, {"Citation": "Fuchs E.C., Weyhenmeyer R., Weiner O.H. Effects of Silibinin and of a Synthetic Analogue on Isolated Rat Hepatic Stellate Cells and Myofibroblasts. Arzneimittelforschung. 1997;47:1383\u20131387.", "ArticleIdList": ["9450168"]}, {"Citation": "Deshmane S.L., Kremlev S., Amini S., Sawaya B.E. Monocyte Chemoattractant Protein-1 (MCP-1): An Overview. J. Interf. Cytokine Res. 2009;29:313\u2013325. doi: 10.1089/jir.2008.0027.", "ArticleIdList": ["10.1089/jir.2008.0027", "PMC2755091", "19441883"]}, {"Citation": "Tsuruta S., Nakamuta M., Enjoji M., Kotoh K., Hiasa K., Egashira K., Nawata H. Anti-Monocyte Chemoattractant Protein-1 Gene Therapy Prevents Dimethylnitrosamine-Induced Hepatic Fibrosis in Rats. Int. J. Mol. Med. 2004;14:837\u2013842. doi: 10.3892/ijmm.14.5.837.", "ArticleIdList": ["10.3892/ijmm.14.5.837", "15492853"]}, {"Citation": "Hemmann S., Graf J., Roderfeld M., Roeb E. Expression of MMPs and TIMPs in Liver Fibrosis-a Systematic Review with Special Emphasis on Anti-Fibrotic Strategies. J. Hepatol. 2007;46:955\u2013975. doi: 10.1016/j.jhep.2007.02.003.", "ArticleIdList": ["10.1016/j.jhep.2007.02.003", "17383048"]}, {"Citation": "Loguercio C., Andreone P., Brisc C., Brisc M.C., Bugianesi E., Chiaramonte M., Cursaro C., Danila M., De Sio I., Floreani A., et al. Silybin Combined with Phosphatidylcholine and Vitamin e in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial. Free Radic. Biol. Med. 2012;52:1658\u20131665. doi: 10.1016/j.freeradbiomed.2012.02.008.", "ArticleIdList": ["10.1016/j.freeradbiomed.2012.02.008", "22343419"]}, {"Citation": "Dehmlow C., Erhard J., De Groot H. Inhibition of Kupffer Cell Functions as an Explanation for the Hepatoprotective Properties of Silibinin. Hepatology. 1996;23:749\u2013754. doi: 10.1002/hep.510230415.", "ArticleIdList": ["10.1002/hep.510230415", "8666328"]}, {"Citation": "Sonnenbichler J., Goldbero M., Hane L., Madubunyi I., Vogl S., Zetl I. Stimulatory Effect of Silibinin on the DNA Synthesis in Partially Hepatectomized Rat Livers: Non-Response in Hepatoma and Other Malign Cell Lines. Biochem. Pharmacol. 1986;35:538\u2013541. doi: 10.1016/0006-2952(86)90233-9.", "ArticleIdList": ["10.1016/0006-2952(86)90233-9", "3004503"]}, {"Citation": "Yormaz S., Bulbuloglu E., Kurutas E.B., Ciralik H., Yuzbasioglu M.F., Yildiz H., Coskuner I., Silay E., Kantarceken B., Goksu M., et al. The Comparison of the Effects of Hepatic Regeneration after Partial Hepatectomy, Silybum Marinaum, Propofol, N-Acetylcysteine and Vitamin E on Liver. Bratislava Med. J. 2012;113:145\u2013151. doi: 10.4149/BLL_2012_035.", "ArticleIdList": ["10.4149/BLL_2012_035", "22428762"]}, {"Citation": "Thakur V., Choudhary M., Garg A., Choudhary N., Jangra A., Budhwar V. Evaluation of a Hydroalcoholic Extract of the Leaves from the Endangered Medicinal Plant Gloriosa Superba Linn. (Colchicaceae) for Its Potential Anti-Diabetic Effect. Arch. Med. 2015;7:1\u20138."}, {"Citation": "Sharma S., Wadhwa K., Choudhary M., Budhwar V. Ethnopharmacological Perspectives of Glucokinase Activators in the Treatment of Diabetes Mellitus. Nat. Prod. Res. 2021:1\u201315. doi: 10.1080/14786419.2021.1931187.", "ArticleIdList": ["10.1080/14786419.2021.1931187", "34044681"]}, {"Citation": "Feng B., Meng R., Huang B., Shen S., Bi Y., Zhu D. Silymarin Alleviates Hepatic Oxidative Stress and Protects against Metabolic Disorders in High-Fat Diet-Fed Mice. Free Radic. Res. 2016;50:314\u2013327. doi: 10.3109/10715762.2015.1116689.", "ArticleIdList": ["10.3109/10715762.2015.1116689", "26758315"]}, {"Citation": "Rahimi R., Karimi J., Khodadadi I., Tayebinia H., Kheiripour N., Hashemnia M., Goli F. Silymarin Ameliorates Expression of Urotensin II (U-II) and Its Receptor (UTR) and Attenuates Toxic Oxidative Stress in the Heart of Rats with Type 2 Diabetes. Biomed. Pharmacother. 2018;101:244\u2013250. doi: 10.1016/j.biopha.2018.02.075.", "ArticleIdList": ["10.1016/j.biopha.2018.02.075", "29494961"]}, {"Citation": "Alabdan M.A. Silymarin Ameliorates Metabolic Risk Factors and Protects against Cardiac Apoptosis in Streptozotocin-Induced Diabetic Rats. Biomed. Biotechnol. 2015;3:20\u201327. doi: 10.12691/bb-3-2-1.", "ArticleIdList": ["10.12691/bb-3-2-1"]}, {"Citation": "Abu-zaiton A.S. Evaluating the Effect of Silybum marianum Extract on Blood Glucose, Liver and Kidney Functions in Diabetic Rats. Adv. Stud. Biol. 2013;5:447\u2013454. doi: 10.12988/asb.2013.3936.", "ArticleIdList": ["10.12988/asb.2013.3936"]}, {"Citation": "Gu M., Zhao P., Huang J., Zhao Y., Wang Y., Li Y., Li Y., Fan S., Ma Y.M., Tong Q., et al. Silymarin Ameliorates Metabolic Dysfunction Associated with Diet-Induced Obesity via Activation of Farnesyl X Receptor. Front. Pharmacol. 2016;7:345. doi: 10.3389/fphar.2016.00345.", "ArticleIdList": ["10.3389/fphar.2016.00345", "PMC5039206", "27733832"]}, {"Citation": "Talaat Elgarf A., Maher Mahdy M., Sabri N.A. Effect of Silymarin Supplementation on Glycemic Control, Lipid Profile and Insulin Resistance in Patients with Type 2 Diabetes Mellitus. Int. J. Adv. Res. 2015;3:812\u2013821."}, {"Citation": "Numan A.T., Hadi N.A., Sh Mohammed N., Hussain S.A. Use of Silymarine as Adjuvant in Type 1 Diabetes Mellitus Patients Poorly Controlled with Insulin. J. Fac. Med. Baghdad. 2010;52:75\u201379. doi: 10.32007/JFACMEDBAGDAD.5211063.", "ArticleIdList": ["10.32007/JFACMEDBAGDAD.5211063"]}, {"Citation": "Velussi M., Cernigoi A.M., Ariella D.M., Dapas F., Caffau C., Zilli M. Long-Term (12 Months) Treatment with an Anti-Oxidant Drug (Silymarin) Is Effective on Hyperinsulinemia, Exogenous Insulin Need and Malondialdehyde Levels in Cirrhotic Diabetic Patients. J. Hepatol. 1997;26:871\u2013879. doi: 10.1016/S0168-8278(97)80255-3.", "ArticleIdList": ["10.1016/S0168-8278(97)80255-3", "9126802"]}, {"Citation": "Huseini H.F., Larijani B., Heshmat R., Fakhrzadeh H., Radjabipour B., Toliat T., Raza M. The Efficacy of Silybum marianum (L.) Gaertn. (Silymarin) in the Treatment of Type II Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial. Phyther. Res. 2006;20:1036\u20131039. doi: 10.1002/ptr.1988.", "ArticleIdList": ["10.1002/ptr.1988", "17072885"]}, {"Citation": "Hussain S.A.R. Silymarin as an Adjunct to Glibenclamide Therapy Improves Long-Term and Postprandial Glycemic Control and Body Mass Index in Type 2 Diabetes. J. Med. Food. 2007;10:543\u2013547. doi: 10.1089/jmf.2006.089.", "ArticleIdList": ["10.1089/jmf.2006.089", "17887949"]}, {"Citation": "Guigas B., Naboulsi R., Villanueva G.R., Taleux N., Lopez-Novoa J.M., Leverve X.M., El-Mir M.Y. The Flavonoid Silibinin Decreases Glucose-6-Phosphate Hydrolysis in Perifused Rat Hepatocytes by an Inhibitory Effect on Glucose-6-Phosphatase. Cell. Physiol. Biochem. 2007;20:925\u2013934. doi: 10.1159/000110453.", "ArticleIdList": ["10.1159/000110453", "17982275"]}, {"Citation": "Feng B., Huang B., Jing Y., Shen S., Feng W., Wang W., Meng R., Zhu D. Silymarin Ameliorates the Disordered Glucose Metabolism of Mice with Diet-Induced Obesity by Activating the Hepatic SIRT1 Pathway. Cell. Signal. 2021;84:110023. doi: 10.1016/j.cellsig.2021.110023.", "ArticleIdList": ["10.1016/j.cellsig.2021.110023", "33901577"]}, {"Citation": "Guo Y., Wang S., Wang Y., Zhu T. Silymarin Improved Diet-Induced Liver Damage and Insulin Resistance by Decreasing Inflammation in Mice. Pharm. Biol. 2016;54:2995\u20133000. doi: 10.1080/13880209.2016.1199042.", "ArticleIdList": ["10.1080/13880209.2016.1199042", "27387273"]}, {"Citation": "Soto C., Raya L., Ju\u00e1rez J., P\u00e9rez J., Gonz\u00e1lez I. Effect of Silymarin in Pdx-1 Expression and the Proliferation of Pancreatic \u03b2-Cells in a Pancreatectomy Model. Phytomedicine. 2014;21:233\u2013239. doi: 10.1016/j.phymed.2013.09.008.", "ArticleIdList": ["10.1016/j.phymed.2013.09.008", "24176839"]}, {"Citation": "Qin N., Hu X., Li S., Wang J., Li Z., Li D., Xu F., Gao M., Hua H. Hypoglycemic Effect of Silychristin A from Silybum marianum Fruit via Protecting Pancreatic Islet \u03b2 Cells from Oxidative Damage and Inhibiting \u03b1-Glucosidase Activity In Vitro and in Rats with Type 1 Diabetes. J. Funct. Foods. 2017;38:168\u2013179. doi: 10.1016/j.jff.2017.09.013.", "ArticleIdList": ["10.1016/j.jff.2017.09.013"]}, {"Citation": "Xu F., Yang J., Negishi H., Sun Y., Li D., Zhang X., Hayashi T., Gao M., Ikeda K., Ikejima T. Silibinin Decreases Hepatic Glucose Production through the Activation of Gut\u2013Brain\u2013Liver Axis in Diabetic Rats. Food Funct. 2018;9:4926\u20134935. doi: 10.1039/C8FO00565F.", "ArticleIdList": ["10.1039/C8FO00565F", "30178798"]}, {"Citation": "Amniattalab A., Malekinejad H., Rezabakhsh A., Rokhsartalab-Azar S., Alizade-Fanalou S. Silymarin: A Novel Natural Agent to Restore Defective Pancreatic \u03b2 Cells in Streptozotocin (STZ)-Induced Diabetic Rats. Iran. J. Pharm. Res. 2016;15:493\u2013500. doi: 10.22037/ijpr.2016.1879.", "ArticleIdList": ["10.22037/ijpr.2016.1879", "PMC5149036", "27980584"]}, {"Citation": "Malekinejad H., Rezabakhsh A., Rahmani F., Hobbenaghi R. Silymarin Regulates the Cytochrome P450 3A2 and Glutathione Peroxides in the Liver of Streptozotocin-Induced Diabetic Rats. Phytomedicine. 2012;19:583\u2013590. doi: 10.1016/j.phymed.2012.02.009.", "ArticleIdList": ["10.1016/j.phymed.2012.02.009", "22445624"]}, {"Citation": "Kim E.J., Kim J., Lee M.Y., Sudhanva M.S., Devakumar S., Jeon Y.J. Silymarin Inhibits Cytokine-Stimulated Pancreatic Beta Cells by Blocking the ERK1/2 Pathway. Biomol. Ther. 2014;22:282\u2013287. doi: 10.4062/biomolther.2014.072.", "ArticleIdList": ["10.4062/biomolther.2014.072", "PMC4131525", "25143805"]}, {"Citation": "Soto C., Raya L., P\u00e9rez J., Gonz\u00e1lez I., P\u00e9rez S. Silymarin Induces Expression of Pancreatic Nkx6.1 Transcription Factor and \u03b2-Cells Neogenesis in a Pancreatectomy Model. Molecules. 2014;19:4654\u20134668. doi: 10.3390/molecules19044654.", "ArticleIdList": ["10.3390/molecules19044654", "PMC6271357", "24739928"]}, {"Citation": "Li H.B., Yang Y.R.Y., Mo Z.J., Ding Y., Jiang W.J. Silibinin Improves Palmitate-Induced Insulin Resistance in C2C12 Myotubes by Attenuating IRS-1/PI3K/AKt Pathway Inhibition. Braz. J. Med. Biol. Res. 2015;48:440\u2013446. doi: 10.1590/1414-431x20144238.", "ArticleIdList": ["10.1590/1414-431x20144238", "PMC4445668", "25760026"]}, {"Citation": "Yang J., Sun Y., Xu F., Liu W., Hayashi T., Onodera S., Tashiro S.I., Ikejima T. Involvement of Estrogen Receptors in Silibinin Protection of Pancreatic \u03b2-Cells from TNF\u03b1- or IL-1\u03b2-Induced Cytotoxicity. Biomed. Pharmacother. 2018;102:344\u2013353. doi: 10.1016/j.biopha.2018.01.128.", "ArticleIdList": ["10.1016/j.biopha.2018.01.128", "29571019"]}, {"Citation": "Sun Y., Yang J., Liu W., Yao G., Xu F., Hayashi T., Onodera S., Ikejima T. Attenuating Effect of Silibinin on Palmitic Acid-Induced Apoptosis and Mitochondrial Dysfunction in Pancreatic \u03b2-Cells Is Mediated by Estrogen Receptor Alpha. Mol. Cell. Biochem. 2019;460:81\u201392. doi: 10.1007/s11010-019-03572-1.", "ArticleIdList": ["10.1007/s11010-019-03572-1", "31183735"]}, {"Citation": "Wang J., Zhang X., Zhang L., Yan T., Wu B., Xu F., Jia Y. Silychristin A Activates Nrf2-HO-1/SOD2 Pathway to Reduce Apoptosis and Improve GLP-1 Production through Upregulation of Estrogen Receptor \u03b1 in GLUTag Cells. Eur. J. Pharmacol. 2020;881:173236. doi: 10.1016/j.ejphar.2020.173236.", "ArticleIdList": ["10.1016/j.ejphar.2020.173236", "32497626"]}, {"Citation": "Stolf A.M., Cardoso C.C., Acco A. Effects of Silymarin on Diabetes Mellitus Complications: A Review. Phyther. Res. 2017;31:366\u2013374. doi: 10.1002/ptr.5768.", "ArticleIdList": ["10.1002/ptr.5768", "28124457"]}, {"Citation": "Tuorkey M.J., El-Desouki N.I., Kamel R.A. Cytoprotective Effect of Silymarin against Diabetes-Induced Cardiomyocyte Apoptosis in Diabetic Rats. Biomed. Environ. Sci. 2015;28:36\u201343. doi: 10.3967/bes2015.004.", "ArticleIdList": ["10.3967/bes2015.004", "25566861"]}, {"Citation": "Meng S., Yang F., Wang Y., Qin Y., Xian H., Che H., Wang L. Silymarin Ameliorates Diabetic Cardiomyopathy via Inhibiting TGF-\u03921/Smad Signaling. Cell Biol. Int. 2019;43:65\u201372. doi: 10.1002/cbin.11079.", "ArticleIdList": ["10.1002/cbin.11079", "30489003"]}, {"Citation": "Sheela N., Jose M.A., Sathyamurthy D., Kumar B.N. Effect of Silymarin on Streptozotocin-Nicotinamide-Induced Type 2 Diabetic Nephropathy in Rats. Iran. J. Kidney Dis. 2013;7:117\u2013123.", "ArticleIdList": ["23485535"]}, {"Citation": "Vessal G., Akmali M., Najafi P., Moein M.R., Sagheb M.M. Silymarin and Milk Thistle Extract May Prevent the Progression of Diabetic Nephropathy in Streptozotocin-Induced Diabetic Rats. Ren. Fail. 2010;32:733\u2013739. doi: 10.3109/0886022X.2010.486488.", "ArticleIdList": ["10.3109/0886022X.2010.486488", "20540643"]}, {"Citation": "Guzel S., Sahinogullari Z.U., Canacankatan N., Antmen S.E., Kibar D., Coskun Yilmaz B. Potential Renoprotective Effects of Silymarin against Vancomycin-Induced Nephrotoxicity in Rats. Drug Chem. Toxicol. 2020;43:630\u2013636. doi: 10.1080/01480545.2019.1584208.", "ArticleIdList": ["10.1080/01480545.2019.1584208", "30862206"]}, {"Citation": "Chen Y., Chen L., Yang T. Silymarin Nanoliposomes Attenuate Renal Injury on Diabetic Nephropathy Rats via Co-Suppressing TGF-\u03b2/Smad and JAK2/STAT3/SOCS1 Pathway. Life Sci. 2021;271:119197. doi: 10.1016/j.lfs.2021.119197.", "ArticleIdList": ["10.1016/j.lfs.2021.119197", "33577847"]}, {"Citation": "Fallahzadeh M.K., Dormanesh B., Sagheb M.M., Roozbeh J., Vessal G., Pakfetrat M., Daneshbod Y., Kamali-Sarvestani E., Lankarani K.B. Effect of Addition of Silymarin to Renin-Angiotensin System Inhibitors on Proteinuria in Type 2 Diabetic Patients with Overt Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial. Am. J. Kidney Dis. 2012;60:896\u2013903. doi: 10.1053/j.ajkd.2012.06.005.", "ArticleIdList": ["10.1053/j.ajkd.2012.06.005", "22770926"]}, {"Citation": "Zhang H.T., Shi K., Baskota A., Zhou F.L., Chen Y.X., Tian H.M. Silybin Reduces Obliterated Retinal Capillaries in Experimental Diabetic Retinopathy in Rats. Eur. J. Pharmacol. 2014;740:233\u2013239. doi: 10.1016/j.ejphar.2014.07.033.", "ArticleIdList": ["10.1016/j.ejphar.2014.07.033", "25066112"]}, {"Citation": "Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71:209\u2013249. doi: 10.3322/caac.21660.", "ArticleIdList": ["10.3322/caac.21660", "33538338"]}, {"Citation": "Mattiuzzi C., Lippi G. Current Cancer Epidemiology. J. Epidemiol. Glob. Health. 2019;9:217\u2013222. doi: 10.2991/jegh.k.191008.001.", "ArticleIdList": ["10.2991/jegh.k.191008.001", "PMC7310786", "31854162"]}, {"Citation": "Elsayed E.A., Sharaf-Eldin M.A., Wadaan M. In Vitro Evaluation of Cytotoxic Activities of Essential Oil from Moringa oleifera Seeds on HeLa, HepG2, MCF-7, CACO-2 and L929 Cell Lines. Asian Pacific J. Cancer Prev. 2015;16:4671\u20134675. doi: 10.7314/APJCP.2015.16.11.4671.", "ArticleIdList": ["10.7314/APJCP.2015.16.11.4671", "26107222"]}, {"Citation": "Liang C., Pan H., Li H., Zhao Y., Feng Y. In Vitro Anticancer Activity and Cytotoxicity Screening of Phytochemical Extracts from Selected Traditional Chinese Medicinal Plants. J. Balk. Union Oncol. 2017;22:543\u2013551.", "ArticleIdList": ["28534383"]}, {"Citation": "Wang X., Zhang Z., Wu S.C. Health Benefits of Silybum marianum: Phytochemistry, Pharmacology, and Applications. J. Agric. Food Chem. 2020;68:11644\u201311664. doi: 10.1021/acs.jafc.0c04791.", "ArticleIdList": ["10.1021/acs.jafc.0c04791", "33045827"]}, {"Citation": "Hosseinabadi T., Lorigooini Z., Tabarzad M., Salehi B., Rodrigues C.F., Martins N., Sharifi-Rad J. Silymarin Antiproliferative and Apoptotic Effects: Insights into Its Clinical Impact in Various Types of Cancer. Phyther. Res. 2019;33:2849\u20132861. doi: 10.1002/ptr.6470.", "ArticleIdList": ["10.1002/ptr.6470", "31407422"]}, {"Citation": "Elyasi S., Shojaee F.S.R., Allahyari A., Karimi G. Topical Silymarin Administration for Prevention of Capecitabine-Induced Hand\u2013Foot Syndrome: A Randomized, Double-Blinded, Placebo-Controlled Clinical Tria. Phyther. Res. 2017;31:1323\u20131329. doi: 10.1002/ptr.5857.", "ArticleIdList": ["10.1002/ptr.5857", "28635153"]}, {"Citation": "Shahbazi F., Sadighi S., Dashti-Khavidaki S., Shahi F., Mirzania M., Abdollahi A., Ghahremani M.H. Effect of Silymarin Administration on Cisplatin Nephrotoxicity: Report from a Pilot, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial. Phyther. Res. 2015;29:1046\u20131053. doi: 10.1002/ptr.5345.", "ArticleIdList": ["10.1002/ptr.5345", "25857366"]}, {"Citation": "Momeni A., Hajigholami A., Geshnizjani S., Kheiri S. Effect of Silymarin in the Prevention of Cisplatin Nephrotoxicity, a Clinical Trial Study. J. Clin. Diagn. Res. 2015;9:11\u201313. doi: 10.7860/JCDR/2015/12776.5789.", "ArticleIdList": ["10.7860/JCDR/2015/12776.5789", "PMC4437094", "26046020"]}, {"Citation": "Elyasi S., Hosseini S., Niazi Moghadam M.R., Aledavood S.A., Karimi G. Effect of Oral Silymarin Administration on Prevention of Radiotherapy Induced Mucositis: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial. Phyther. Res. 2016;30:1879\u20131885. doi: 10.1002/ptr.5704.", "ArticleIdList": ["10.1002/ptr.5704", "27555604"]}, {"Citation": "Karbasforooshan H., Hosseini S., Elyasi S., Fani Pakdel A., Karimi G. Topical Silymarin Administration for Prevention of Acute Radiodermatitis in Breast Cancer Patients: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Phyther. Res. 2019;33:379\u2013386. doi: 10.1002/ptr.6231.", "ArticleIdList": ["10.1002/ptr.6231", "30479044"]}, {"Citation": "Becker-Schiebe M., Mengs U., Schaefer M., Bulitta M., Hoffmann W. Topical Use of a Silymarin-Based Preparation to Prevent Radiodermatitis: Results of a Prospective Study in Breast Cancer Patients. Strahlenther. Onkol. 2011;187:485\u2013491. doi: 10.1007/s00066-011-2204-z.", "ArticleIdList": ["10.1007/s00066-011-2204-z", "21786113"]}, {"Citation": "Imai-Sumida M., Chiyomaru T., Majid S., Saini S., Nip H., Dahiya R., Tanaka Y., Yamamura S. Silibinin Suppresses Bladder Cancer through Down-Regulation of Actin Cytoskeleton and PI3K/Akt Signaling Pathways. Oncotarget. 2017;8:92032\u201392042. doi: 10.18632/oncotarget.20734.", "ArticleIdList": ["10.18632/oncotarget.20734", "PMC5696161", "29190895"]}, {"Citation": "Kim S.H., Choo G.-S., Yoo E.S., Woo J.S., Lee J.H., Han S.H., Jung S.H., Kim H.J., Jung J.Y. Silymarin Inhibits Proliferation of Human Breast Cancer Cells via Regulation of the MAPK Signaling Pathway and Induction of Apoptosis. Oncol. Lett. 2021;21:492. doi: 10.3892/ol.2021.12753.", "ArticleIdList": ["10.3892/ol.2021.12753", "PMC8100955", "33968208"]}, {"Citation": "Permana M.Y., Soediro T.M., Louisa M. Silymarin Increases the Sensitivity of Breast Cancer Cells to Doxorubicin in Doxorubicin-Induced MCF-7 Cells by Inhibiting Breast Cancer Resistance Protein Expression. J. Phys. Conf. Ser. 2018;1073:032055. doi: 10.1088/1742-6596/1073/3/032055.", "ArticleIdList": ["10.1088/1742-6596/1073/3/032055"]}, {"Citation": "Forghani P., Khorramizadeh M.R., Waller E.K. Silibinin Inhibits Accumulation of Myeloid-Derived Suppressor Cells and Tumor Growth of Murine Breast Cancer. Cancer Med. 2014;3:215\u2013224. doi: 10.1002/cam4.186.", "ArticleIdList": ["10.1002/cam4.186", "PMC3987072", "24574320"]}, {"Citation": "Si L., Fu J., Liu W., Hayashi T., Nie Y., Mizuno K., Hattori S., Fujisaki H., Onodera S., Ikejima T. Silibinin Inhibits Migration and Invasion of Breast Cancer MDA-MB-231 Cells through Induction of Mitochondrial Fusion. Mol. Cell. Biochem. 2020;463:189\u2013201. doi: 10.1007/s11010-019-03640-6.", "ArticleIdList": ["10.1007/s11010-019-03640-6", "31612353"]}, {"Citation": "Dastpeyman M., Motamed N., Azadmanesh K., Mostafavi E., Kia V., Jahanian-Najafabadi A., Shokrgozar M.A. Inhibition of Silibinin on Migration and Adhesion Capacity of Human Highly Metastatic Breast Cancer Cell Line, MDA-MB-231, by Evaluation of \u03921-Integrin and Downstream Molecules, Cdc42, Raf-1 and D4GDI. Med. Oncol. 2012;29:2512\u20132518. doi: 10.1007/s12032-011-0113-8.", "ArticleIdList": ["10.1007/s12032-011-0113-8", "22101790"]}, {"Citation": "Byun H.J., Darvin P., Kang D.Y., Sp N., Joung Y.H., Park J.H., Kim S.J., Yang Y.M. Silibinin Downregulates MMP2 Expression via Jak2/STAT3 Pathway and Inhibits the Migration and Invasive Potential in MDA-MB-231 Cells. Oncol. Rep. 2017;37:3270\u20133278. doi: 10.3892/or.2017.5588.", "ArticleIdList": ["10.3892/or.2017.5588", "28440514"]}, {"Citation": "Lee S.O., Jeong Y.J., Im H.G., Kim C.H., Chang Y.C., Lee I.S. Silibinin Suppresses PMA-Induced MMP-9 Expression by Blocking the AP-1 Activation via MAPK Signaling Pathways in MCF-7 Human Breast Carcinoma Cells. Biochem. Biophys. Res. Commun. 2007;354:165\u2013171. doi: 10.1016/j.bbrc.2006.12.181.", "ArticleIdList": ["10.1016/j.bbrc.2006.12.181", "17214970"]}, {"Citation": "Kim S., Choi J.H., Lim H.I., Lee S.K., Kim W.W., Kim J.S., Kim J.H., Choe J.H., Yang J.H., Nam S.J., et al. Silibinin Prevents TPA-Induced MMP-9 Expression and VEGF Secretion by Inactivation of the Raf/MEK/ERK Pathway in MCF-7 Human Breast Cancer Cells. Phytomedicine. 2009;16:573\u2013580. doi: 10.1016/j.phymed.2008.11.006.", "ArticleIdList": ["10.1016/j.phymed.2008.11.006", "19181503"]}, {"Citation": "Lu W., Lin C., King T.D., Chen H., Reynolds R.C., Li Y. Silibinin Inhibits Wnt/\u03b2-Catenin Signaling by Suppressing Wnt Co-Receptor LRP6 Expression in Human Prostate and Breast Cancer Cells. Cell. Signal. 2012;24:2291\u20132296. doi: 10.1016/j.cellsig.2012.07.009.", "ArticleIdList": ["10.1016/j.cellsig.2012.07.009", "PMC3466371", "22820499"]}, {"Citation": "Kauntz H., Bousserouel S., Gosse F., Marescaux J., Raul F. Silibinin, a Natural Flavonoid, Modulates the Early Expression of Chemoprevention Biomarkers in a Preclinical Model of Colon Carcinogenesis. Int. J. Oncol. 2012;41:849\u2013854. doi: 10.3892/ijo.2012.1526.", "ArticleIdList": ["10.3892/ijo.2012.1526", "PMC3582883", "22735354"]}, {"Citation": "Kauntz H., Bousserouel S., Goss\u00e9 F., Raul F. Silibinin Triggers Apoptotic Signaling Pathways and Autophagic Survival Response in Human Colon Adenocarcinoma Cells and Their Derived Metastatic Cells. Apoptosis. 2011;16:1042\u20131053. doi: 10.1007/s10495-011-0631-z.", "ArticleIdList": ["10.1007/s10495-011-0631-z", "21779837"]}, {"Citation": "Eo H.J., Park G.H., Song H.M., Lee J.W., Kim M.K., Lee M.H., Lee J.R., Koo J.S., Jeong J.B. Silymarin Induces Cyclin D1 Proteasomal Degradation via Its Phosphorylation of Threonine-286 in Human Colorectal Cancer Cells. Int. Immunopharmacol. 2015;24:1\u20136. doi: 10.1016/j.intimp.2014.11.009.", "ArticleIdList": ["10.1016/j.intimp.2014.11.009", "25479723"]}, {"Citation": "Eo H.J., Jeong J.B., Koo J.S., Jeong H.J. Silymarin-Mediated Degradation of c-Myc Contributes to the Inhibition of Cell Proliferation in Human Colorectal Cancer Cells. Korean J. Plant Resour. 2017;30:265\u2013271. doi: 10.7732/kjpr.2017.30.3.265.", "ArticleIdList": ["10.7732/kjpr.2017.30.3.265"]}, {"Citation": "Wang J.Y., Chang C.C., Chiang C.C., Chen W.M., Hung S.C. Silibinin Suppresses the Maintenance of Colorectal Cancer Stem-like Cells by Inhibiting PP2A/AKT/MTOR Pathways. J. Cell. Biochem. 2012;113:1733\u20131743. doi: 10.1002/jcb.24043.", "ArticleIdList": ["10.1002/jcb.24043", "22213051"]}, {"Citation": "Kim S.H., Choo G.S., Yoo E.S., Woo J.S., Han S.H., Lee J.H., Jung J.Y. Silymarin Induces Inhibition of Growth and Apoptosis through Modulation of the MAPK Signaling Pathway in AGS Human Gastric Cancer Cells. Oncol. Rep. 2019;42:1904\u20131914. doi: 10.3892/or.2019.7295.", "ArticleIdList": ["10.3892/or.2019.7295", "PMC6775811", "31485597"]}, {"Citation": "Li R., Yu J., Wang C. Silibinin Promotes the Apoptosis of Gastric Cancer BGC823 Cells through Caspase Pathway. J. BUON. 2017;22:1148\u20131153.", "ArticleIdList": ["29135096"]}, {"Citation": "Wang Y.X., Cai H., Jiang G., Zhou T.B., Wu H. Silibinin Inhibits Proliferation, Induces Apoptosis and Causes Cell Cycle Arrest in Human Gastric Cancer MGC803 Cells via STAT3 Pathway Inhibition. Asian Pacific J. Cancer Prev. 2014;15:6791\u20136798. doi: 10.7314/APJCP.2014.15.16.6791.", "ArticleIdList": ["10.7314/APJCP.2014.15.16.6791", "25169527"]}, {"Citation": "Zappavigna S., Vanacore D., Lama S., Potenza N., Russo A., Ferranti P., Dallio M., Federico A., Loguercio C., Sperlongano P., et al. Silybin-Induced Apoptosis Occurs in Parallel to the Increase of Ceramides Synthesis and Mirnas Secretion in Human Hepatocarcinoma Cells. Int. J. Mol. Sci. 2019;20:2190. doi: 10.3390/ijms20092190.", "ArticleIdList": ["10.3390/ijms20092190", "PMC6539179", "31058823"]}, {"Citation": "Gu H.R., Park S.C., Choi S., Lee J.C., Kim Y.C., Han C.J., Kim J., Yang K.Y., Kim Y.J., Noh G.Y., et al. Combined Treatment with Silibinin and Either Sorafenib or Gefitinib Enhances Their Growth-Inhibiting Effects in Hepatocellular Carcinoma Cells. Clin. Mol. Hepatol. 2015;21:49\u201359. doi: 10.3350/cmh.2015.21.1.49.", "ArticleIdList": ["10.3350/cmh.2015.21.1.49", "PMC4379197", "25834802"]}, {"Citation": "Bektur Aykanat N.E., Kacar S., Karakaya S., Sahinturk V. Silymarin Suppresses HepG2 Hepatocarcinoma Cell Progression through Downregulation of Slit-2/Robo-1 Pathway. Pharmacol. Rep. 2020;72:199\u2013207. doi: 10.1007/s43440-019-00040-x.", "ArticleIdList": ["10.1007/s43440-019-00040-x", "32016841"]}, {"Citation": "Zhang S., Yang Y., Liang Z., Duan W., Yang J., Yan J., Wang N., Feng W., Ding M., Nie Y., et al. Silybin-Mediated Inhibition of Notch Signaling Exerts Antitumor Activity in Human Hepatocellular Carcinoma Cells. PLoS ONE. 2013;8:83699. doi: 10.1371/journal.pone.0083699.", "ArticleIdList": ["10.1371/journal.pone.0083699", "PMC3873967", "24386256"]}, {"Citation": "Ramakrishnan G., Jagan S., Kamaraj S., Anandakumar P., Devaki T. Silymarin Attenuated Mast Cell Recruitment Thereby Decreased the Expressions of Matrix Metalloproteinases-2 and 9 in Rat Liver Carcinogenesis. Invest. New Drugs. 2009;27:233\u2013240. doi: 10.1007/s10637-008-9163-y.", "ArticleIdList": ["10.1007/s10637-008-9163-y", "18665326"]}, {"Citation": "Yang X., Li X., An L., Bai B., Chen J. Silibinin Induced the Apoptosis of Hep-2 Cells via Oxidative Stress and down-Regulating Survivin Expression. Eur. Arch. Oto-Rhino-Laryngol. 2013;270:2289\u20132297. doi: 10.1007/s00405-013-2444-x.", "ArticleIdList": ["10.1007/s00405-013-2444-x", "23580032"]}, {"Citation": "Faezizadeh Z., Mesbah-Namin S.A.R., Allameh A. The Effect of Silymarin on Telomerase Activity in the Human Leukemia Cell Line K562. Planta Med. 2012;78:899\u2013902. doi: 10.1055/s-0031-1298464.", "ArticleIdList": ["10.1055/s-0031-1298464", "22532022"]}, {"Citation": "Guo S., Bai X., Liu Y., Shi S., Wang X., Zhan Y., Kang X., Chen Y., An H. Inhibition of TMEM16A by Natural Product Silibinin: Potential Lead Compounds for Treatment of Lung Adenocarcinoma. Front. Pharmacol. 2021;12:736. doi: 10.3389/fphar.2021.643489.", "ArticleIdList": ["10.3389/fphar.2021.643489", "PMC8079988", "33935737"]}, {"Citation": "Won D.H., Kim L.H., Jang B., Yang I.H., Kwon H.J., Jin B., Oh S.H., Kang J.H., Hong S.D., Shin J.A., et al. In Vitro and In Vivo Anti-Cancer Activity of Silymarin on Oral Cancer. Tumor Biol. 2018;40:1010428318776170. doi: 10.1177/1010428318776170.", "ArticleIdList": ["10.1177/1010428318776170", "29764340"]}, {"Citation": "Choi E.S., Oh S., Jang B., Yu H.J., Shin J.A., Cho N.P., Yang I.H., Won D.H., Kwon H.J., Hong S.D., et al. Silymarin and Its Active Component Silibinin Act as Novel Therapeutic Alternatives for Salivary Gland Cancer by Targeting the ERK1/2-Bim Signaling Cascade. Cell. Oncol. 2017;40:235\u2013246. doi: 10.1007/s13402-017-0318-8.", "ArticleIdList": ["10.1007/s13402-017-0318-8", "28401485"]}, {"Citation": "Iyengar R.M., Devaraj E. Silibinin Triggers the Mitochondrial Pathway of Apoptosis in Human Oral Squamous Carcinoma Cells. Asian Pacific J. Cancer Prev. 2020;21:1877\u20131882. doi: 10.31557/APJCP.2020.21.7.1877.", "ArticleIdList": ["10.31557/APJCP.2020.21.7.1877", "PMC7573425", "32711410"]}, {"Citation": "Fan L., Ma Y., Liu Y., Zheng D., Huang G. Silymarin Induces Cell Cycle Arrest and Apoptosis in Ovarian Cancer Cells. Eur. J. Pharmacol. 2014;743:79\u201388. doi: 10.1016/j.ejphar.2014.09.019.", "ArticleIdList": ["10.1016/j.ejphar.2014.09.019", "25242120"]}, {"Citation": "Kacar S., Bektur Aykanat N.E., Sahinturk V. Silymarin Inhibited DU145 Cells by Activating SLIT2 Protein and Suppressing Expression of CXCR4. Med. Oncol. 2020;37:18. doi: 10.1007/s12032-020-1343-4.", "ArticleIdList": ["10.1007/s12032-020-1343-4", "32062757"]}, {"Citation": "Singh R.P., Tyagi A.K., Zhao J., Agarwal R. Silymarin Inhibits Growth and Causes Regression of Established Skin Tumors in SENCAR Mice via Modulation of Mitogen-Activated Protein Kinases and Induction of Apoptosis. Carcinogenesis. 2002;23:499\u2013510. doi: 10.1093/carcin/23.3.499.", "ArticleIdList": ["10.1093/carcin/23.3.499", "11895866"]}, {"Citation": "Vaid M., Prasad R., Sun Q., Katiyar S.K. Silymarin Targets B-Catenin Signaling in Blocking Migration/Invasion of Human Melanoma Cells. PLoS ONE. 2011;6:e23000. doi: 10.1371/journal.pone.0023000.", "ArticleIdList": ["10.1371/journal.pone.0023000", "PMC3145779", "21829575"]}, {"Citation": "Khan A.Q., Khan R., Tahir M., Rehman M.U., Lateef A., Ali F., Hamiza O.O., Hasan S.K., Sultana S. Silibinin Inhibits Tumor Promotional Triggers and Tumorigenesis against Chemically Induced Two-Stage Skin Carcinogenesis in Swiss Albino Mice: Possible Role of Oxidative Stress and Inflammation. Nutr. Cancer. 2014;66:249\u2013258. doi: 10.1080/01635581.2014.863365.", "ArticleIdList": ["10.1080/01635581.2014.863365", "24364787"]}, {"Citation": "Vaid M., Singh T., Prasad R., Katiyar S.K. Silymarin Inhibits Melanoma Cell Growth Both In Vitro and In Vivo by Targeting Cell Cycle Regulators, Angiogenic Biomarkers and Induction of Apoptosis. Mol. Carcinog. 2015;54:1328\u20131339. doi: 10.1002/mc.22208.", "ArticleIdList": ["10.1002/mc.22208", "25174976"]}, {"Citation": "Kalla P.K., Chitti S., Aghamirzaei S.T., Senthilkumar R., Arjunan S. Anti-Cancer Activity of Silymarin on MCF-7 and NCIH-23 Cell Lines. Adv. Biol. Res. 2014;8:57\u201361. doi: 10.5829/idosi.abr.2014.8.2.82286.", "ArticleIdList": ["10.5829/idosi.abr.2014.8.2.82286"]}, {"Citation": "Vinh P.Q., Sugie S., Tanaka T., Hara A., Yamada Y., Katayama M., Deguchi T., Mori H. Chemopreventive Effects of a Flavonoid Antioxidant Silymarin on N-Butyl-N-(4-Hydroxybutyl)Nitrosamine-Induced Urinary Bladder Carcinogenesis in Male ICR Mice. Jpn. J. Cancer Res. 2002;93:42\u201349. doi: 10.1111/j.1349-7006.2002.tb01199.x.", "ArticleIdList": ["10.1111/j.1349-7006.2002.tb01199.x", "PMC5926872", "11802807"]}, {"Citation": "Feng N., Luo J., Guo X. Silybin Suppresses Cell Proliferation and Induces Apoptosis of Multiple Myeloma Cells via the PI3K/Akt/MTOR Signaling Pathway. Mol. Med. Rep. 2016;13:3243\u20133248. doi: 10.3892/mmr.2016.4887.", "ArticleIdList": ["10.3892/mmr.2016.4887", "26936429"]}, {"Citation": "Huang Q., Wu L.J., Tashiro S.I., Onodera S., Li L.H., Ikejima T. Silymarin Augments Human Cervical Cancer HeLa Cell Apoptosis via P38/JNK MAPK Pathways in Serum-Free Medium. J. Asian Nat. Prod. Res. 2005;7:701\u2013709. doi: 10.1080/1028602042000324862.", "ArticleIdList": ["10.1080/1028602042000324862", "16176902"]}, {"Citation": "Deep G., Oberlies N.H., Kroll D.J., Agarwal R. Identifying the Differential Effects of Silymarin Constituents on Cell Growth and Cell Cycle Regulatory Molecules in Human Prostate Cancer Cells. Int. J. Cancer. 2008;123:41\u201350. doi: 10.1002/ijc.23485.", "ArticleIdList": ["10.1002/ijc.23485", "18435416"]}, {"Citation": "Bhatia N., Agarwal R. Detrimental Effect of Cancer Preventive Phytochemicals Silymarin, Genistein and Epigallocatechin 3-Gallate on Epigenetic Events in Human Prostate Carcinoma DU145 Cells. Prostate. 2001;46:98\u2013107. doi: 10.1002/1097-0045(20010201)46:2<98::AID-PROS1013>3.0.CO;2-K.", "ArticleIdList": ["10.1002/1097-0045(20010201)46:2<98::AID-PROS1013>3.0.CO;2-K", "11170137"]}, {"Citation": "Katiyar S.K., Roy A.M., Baliga M.S. Silymarin Induces Apoptosis Primarily through a P53-Dependent Pathway Involving Bcl-2/Bax, Cytochrome c Release, and Caspase Activation. Mol. Cancer Ther. 2005;4:207\u2013216. doi: 10.1158/1535-7163.207.4.2.", "ArticleIdList": ["10.1158/1535-7163.207.4.2", "15713892"]}, {"Citation": "Zi X., Agarwal R. Modulation of Mitogen-Activated Protein Kinase Activation and Cell Cycle Regulators by the Potent Skin Cancer Preventive Agent Silymarin. Biochem. Biophys. Res. Commun. 1999;263:528\u2013536. doi: 10.1006/bbrc.1999.1398.", "ArticleIdList": ["10.1006/bbrc.1999.1398", "10491326"]}, {"Citation": "Vaid M., Katiyar S.K. Molecular Mechanisms of Inhibition of Photocarcinogenesis by Silymarin, a Phytochemical from Milk Thistle (Silybum marianum L. Gaertn.) (Review) Int. J. Oncol. 2010;36:1053\u20131060. doi: 10.3892/ijo_00000586.", "ArticleIdList": ["10.3892/ijo_00000586", "PMC2852174", "20372777"]}, {"Citation": "Zhu Z., Sun G. Silymarin Mitigates Lung Impairments in a Rat Model of Acute Respiratory Distress Syndrome. Inflammopharmacology. 2018;26:747\u2013754. doi: 10.1007/s10787-017-0407-3.", "ArticleIdList": ["10.1007/s10787-017-0407-3", "29098546"]}, {"Citation": "Ramakrishnan G., Lo Muzio L., Elinos-B\u00e1ez C.M., Jagan S., Augustine T.A., Kamaraj S., Anandakumar P., Devaki T. Silymarin Inhibited Proliferation and Induced Apoptosis in Hepatic Cancer Cells. Cell Prolif. 2009;42:229\u2013240. doi: 10.1111/j.1365-2184.2008.00581.x.", "ArticleIdList": ["10.1111/j.1365-2184.2008.00581.x", "PMC6495958", "19317806"]}, {"Citation": "Aayadi H., Mittal S.P.K., Deshpande A., Gore M., Ghaskadbi S.S. Protective Effect of Geraniin against Carbon Tetrachloride Induced Acute Hepatotoxicity in Swiss Albino Mice. Biochem. Biophys. Res. Commun. 2017;487:62\u201367. doi: 10.1016/j.bbrc.2017.04.013.", "ArticleIdList": ["10.1016/j.bbrc.2017.04.013", "28396147"]}, {"Citation": "Kim E.K., Choi E.J. Pathological Roles of MAPK Signaling Pathways in Human Diseases. Biochim. Biophys. Acta-Mol. Basis Dis. 2010;1802:396\u2013405. doi: 10.1016/j.bbadis.2009.12.009.", "ArticleIdList": ["10.1016/j.bbadis.2009.12.009", "20079433"]}, {"Citation": "Kauntz H., Bousserouel S., Goss\u00e9 F., Raul F. The Flavonolignan Silibinin Potentiates TRAIL-Induced Apoptosis in Human Colon Adenocarcinoma and in Derived TRAIL-Resistant Metastatic Cells. Apoptosis. 2012;17:797\u2013809. doi: 10.1007/s10495-012-0731-4.", "ArticleIdList": ["10.1007/s10495-012-0731-4", "22555452"]}, {"Citation": "Zhang M., Liu Y., Gao Y., Li S. Silibinin-Induced Glioma Cell Apoptosis by PI3K-Mediated but Akt-Independent Downregulation of FoxM1 Expression. Eur. J. Pharmacol. 2015;765:346\u2013354. doi: 10.1016/j.ejphar.2015.08.057.", "ArticleIdList": ["10.1016/j.ejphar.2015.08.057", "26342429"]}, {"Citation": "Shapiro G.I. Cyclin-Dependent Kinase Pathways as Targets for Cancer Treatment. J. Clin. Oncol. 2006;24:1770\u20131783. doi: 10.1200/JCO.2005.03.7689.", "ArticleIdList": ["10.1200/JCO.2005.03.7689", "16603719"]}, {"Citation": "Vijayaraghavan S., Moulder S., Keyomarsi K., Layman R.M. Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions. Target. Oncol. 2018;13:21\u201338. doi: 10.1007/s11523-017-0541-2.", "ArticleIdList": ["10.1007/s11523-017-0541-2", "29218622"]}, {"Citation": "Cui H., Li T.L., Guo H.F., Wang J.L., Xue P., Zhang Y., Fan J.H., Li Z.P., Gao Y.J. Silymarin-Mediated Regulation of the Cell Cycle and DNA Damage Response Exerts Antitumor Activity in Human Hepatocellular Carcinoma. Oncol. Lett. 2018;15:885\u2013892. doi: 10.3892/ol.2017.7425.", "ArticleIdList": ["10.3892/ol.2017.7425", "PMC5772825", "29399153"]}, {"Citation": "Jung Y.S., Park J. Il Wnt Signaling in Cancer: Therapeutic Targeting of Wnt Signaling beyond \u03b2-Catenin and the Destruction Complex. Exp. Mol. Med. 2020;52:183\u2013191. doi: 10.1038/s12276-020-0380-6.", "ArticleIdList": ["10.1038/s12276-020-0380-6", "PMC7062731", "32037398"]}, {"Citation": "Zhang Y., Wang X. Targeting the Wnt/\u03b2-Catenin Signaling Pathway in Cancer. J. Hematol. Oncol. 2020;13:165. doi: 10.1186/s13045-020-00990-3.", "ArticleIdList": ["10.1186/s13045-020-00990-3", "PMC7716495", "33276800"]}, {"Citation": "Zhou L., Wang D.S., Li Q.J., Sun W., Zhang Y., Dou K.F. The Down-Regulation of Notch1 Inhibits the Invasion and Migration of Hepatocellular Carcinoma Cells by Inactivating the Cyclooxygenase-2/Snail/E- Cadherin Pathway In Vitro. Dig. Dis. Sci. 2013;58:1016\u20131025. doi: 10.1007/s10620-012-2434-7.", "ArticleIdList": ["10.1007/s10620-012-2434-7", "23053901"]}, {"Citation": "de los Fayos Alons Alonso I., Liang H.C., Turner S.D., Lagger S., Merkel O., Kenner L. The Role of Activator Protein-1 (AP-1) Family Members in CD30-Positive Lymphomas. Cancers. 2018;10:93. doi: 10.3390/cancers10040093.", "ArticleIdList": ["10.3390/cancers10040093", "PMC5923348", "29597249"]}, {"Citation": "Chatterjee S., Behnam Azad B., Nimmagadda S. Advances in Cancer Research. Volume 124. Academic Press; Cambridge, MA, USA: 2014. The Intricate Role of CXCR4 in Cancer; pp. 31\u201382.", "ArticleIdList": ["PMC4322894", "25287686"]}, {"Citation": "Bosch-Barrera J., Queralt B., Menendez J.A. Targeting STAT3 with Silibinin to Improve Cancer Therapeutics. Cancer Treat. Rev. 2017;58:61\u201369. doi: 10.1016/j.ctrv.2017.06.003.", "ArticleIdList": ["10.1016/j.ctrv.2017.06.003", "28686955"]}, {"Citation": "Kittur S., Wilasrusmee S., Pedersen W.A., Mattson M.P., Straube-West K., Wilasrusmee C., Jubelt B., Kittur D.S. Neurotrophic and Neuroprotective Effects of Milk Thistle (Silybum marianum) on Neurons in Culture. J. Mol. Neurosci. 2002;18:265\u2013269. doi: 10.1385/JMN:18:3:265.", "ArticleIdList": ["10.1385/JMN:18:3:265", "12059045"]}, {"Citation": "Darvesh A.S., Carroll R.T., Bishayee A., Geldenhuys W.J., Van Der Schyf C.J. Oxidative Stress and Alzheimer\u2019s Disease: Dietary Polyphenols as Potential Therapeutic Agents. Expert Rev. Neurother. 2010;10:729\u2013745. doi: 10.1586/ern.10.42.", "ArticleIdList": ["10.1586/ern.10.42", "20420493"]}, {"Citation": "Song X., Zhou B., Cui L., Lei D., Zhang P., Yao G., Xia M., Hayashi T., Hattori S., Ushiki-Kaku Y., et al. Silibinin Ameliorates A\u03b225-35-Induced Memory Deficits in Rats by Modulating Autophagy and Attenuating Neuroinflammation as Well as Oxidative Stress. Neurochem. Res. 2017;42:1073\u20131083. doi: 10.1007/s11064-016-2141-4.", "ArticleIdList": ["10.1007/s11064-016-2141-4", "28004303"]}, {"Citation": "Al-Enazi M.M. Neuroprotective Effect of Silymarin by Modulation of Endogenous Biomarkers in Streptozotocin Induced Painful Diabetic Neuropathy. Br. J. Pharmacol. Toxicol. 2013;4:110\u2013120. doi: 10.19026/bjpt.4.5372.", "ArticleIdList": ["10.19026/bjpt.4.5372"]}, {"Citation": "Song X., Zhou B., Zhang P., Lei D., Wang Y., Yao G., Hayashi T., Xia M., Tashiro S.I., Onodera S., et al. Protective Effect of Silibinin on Learning and Memory Impairment in LPS-Treated Rats via ROS\u2013BDNF\u2013TrkB Pathway. Neurochem. Res. 2016;41:1662\u20131672. doi: 10.1007/s11064-016-1881-5.", "ArticleIdList": ["10.1007/s11064-016-1881-5", "26961891"]}, {"Citation": "Thakare V.N., Aswar M.K., Kulkarni Y.P., Patil R.R., Patel B.M. Silymarin Ameliorates Experimentally Induced Depressive like Behavior in Rats: Involvement of Hippocampal BDNF Signaling, Inflammatory Cytokines and Oxidative Stress Response. Physiol. Behav. 2017;179:401\u2013410. doi: 10.1016/j.physbeh.2017.07.010.", "ArticleIdList": ["10.1016/j.physbeh.2017.07.010", "28711395"]}, {"Citation": "Haddadi R., Nayebi A.M., Farajniya S., Brooshghalan S.E., Sharifi H. Silymarin Improved 6-OHDA-Induced Motor Impairment in Hemi-Parkisonian Rats: Behavioral and Molecular Study. DARU J. Pharm. Sci. 2014;22:38. doi: 10.1186/2008-2231-22-38.", "ArticleIdList": ["10.1186/2008-2231-22-38", "PMC4001109", "24726284"]}, {"Citation": "Galhardi F., Mesquita K., Monserrat J.M., Barros D.M. Effect of Silymarin on Biochemical Parameters of Oxidative Stress in Aged and Young Rat Brain. Food Chem. Toxicol. 2009;47:2655\u20132660. doi: 10.1016/j.fct.2009.07.030.", "ArticleIdList": ["10.1016/j.fct.2009.07.030", "19647779"]}, {"Citation": "Nencini C., Giorgi G., Micheli L. Protective Effect of Silymarin on Oxidative Stress in Rat Brain. Phytomedicine. 2007;14:129\u2013135. doi: 10.1016/j.phymed.2006.02.005.", "ArticleIdList": ["10.1016/j.phymed.2006.02.005", "16638633"]}, {"Citation": "Lu C.W., Lin T.Y., Chiu K.M., Lee M.Y., Huang J.H., Wang S.J. Silymarin Inhibits Glutamate Release and Prevents against Kainic Acid-Induced Excitotoxic Injury in Rats. Biomedicines. 2020;8:486. doi: 10.3390/biomedicines8110486.", "ArticleIdList": ["10.3390/biomedicines8110486", "PMC7695262", "33182349"]}, {"Citation": "Ullah H., Khan H. Anti-Parkinson Potential of Silymarin: Mechanistic Insight and Therapeutic Standing. Front. Pharmacol. 2018;9:422. doi: 10.3389/fphar.2018.00422.", "ArticleIdList": ["10.3389/fphar.2018.00422", "PMC5934474", "29755356"]}, {"Citation": "Thome A.D., Harms A.S., Volpicelli-Daley L.A., Standaert D.G. MicroRNA-155 Regulates Alpha-Synuclein-Induced Inflammatory Responses in Models of Parkinson Disease. J. Neurosci. 2016;36:2383\u20132390. doi: 10.1523/JNEUROSCI.3900-15.2016.", "ArticleIdList": ["10.1523/JNEUROSCI.3900-15.2016", "PMC4764660", "26911687"]}, {"Citation": "P\u00e9rez-H J., Carrillo-S C., Garc\u00eda E., Ruiz-Mar G., P\u00e9rez-Tamayo R., Chavarr\u00eda A. Neuroprotective Effect of Silymarin in a MPTP Mouse Model of Parkinson\u2019s Disease. Toxicology. 2014;319:38\u201343. doi: 10.1016/j.tox.2014.02.009.", "ArticleIdList": ["10.1016/j.tox.2014.02.009", "24607817"]}, {"Citation": "Baluchnejadmojarad T., Roghani M., Mafakheri M. Neuroprotective Effect of Silymarin in 6-Hydroxydopamine Hemi-Parkinsonian Rat: Involvement of Estrogen Receptors and Oxidative Stress. Neurosci. Lett. 2010;480:206\u2013210. doi: 10.1016/j.neulet.2010.06.038.", "ArticleIdList": ["10.1016/j.neulet.2010.06.038", "20600617"]}, {"Citation": "Srivastava S., Sammi S.R., Laxman T.S., Pant A., Nagar A., Trivedi S., Bhatta R.S., Tandon S., Pandey R. Silymarin Promotes Longevity and Alleviates Parkinson\u2019s Associated Pathologies in Caenorhabditis Elegans. J. Funct. Foods. 2017;31:32\u201343. doi: 10.1016/j.jff.2017.01.029.", "ArticleIdList": ["10.1016/j.jff.2017.01.029"]}, {"Citation": "Mazzio E.A., Harris N., Soliman K.F.A. Food Constituents Attenuate Monoamine Oxidase Activity and Peroxide Levels in C6 Astrocyte Cells. Planta Med. 1998;64:603\u2013606. doi: 10.1055/s-2006-957530.", "ArticleIdList": ["10.1055/s-2006-957530", "9810264"]}, {"Citation": "de Oliveira D.R., Schaffer L.F., Busanello A., Barbosa C.P., Peroza L.R., de Freitas C.M., Krum B.N., Bressan G.N., Boligon A.A., Athayde M.L., et al. Silymarin Has Antioxidant Potential and Changes the Activity of Na+/K+-ATPase and Monoamine Oxidase In Vitro. Ind. Crops Prod. 2015;70:347\u2013355. doi: 10.1016/j.indcrop.2015.03.060.", "ArticleIdList": ["10.1016/j.indcrop.2015.03.060"]}, {"Citation": "Wang M.J., Lin W.W., Chen H.L., Chang Y.H., Ou H.C., Kuo J.S., Hong J.S., Jeng K.C.G. Silymarin Protects Dopaminergic Neurons against Lipopolysaccharide-Induced Neurotoxicity by Inhibiting Microglia Activation. Eur. J. Neurosci. 2002;16:2103\u20132112. doi: 10.1046/j.1460-9568.2002.02290.x.", "ArticleIdList": ["10.1046/j.1460-9568.2002.02290.x", "12473078"]}, {"Citation": "Tripathi M.K., Rasheed M.S.U., Mishra A.K., Patel D.K., Singh M.P. Silymarin Protects against Impaired Autophagy Associated with 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Parkinsonism. J. Mol. Neurosci. 2020;70:276\u2013283. doi: 10.1007/s12031-019-01431-8.", "ArticleIdList": ["10.1007/s12031-019-01431-8", "31732923"]}, {"Citation": "Aboelwafa H.R., El-Kott A.F., Abd-Ella E.M., Yousef H.N. The Possible Neuroprotective Effect of Silymarin against Aluminum Chloride-Prompted Alzheimer\u2019s-like Disease in Rats. Brain Sci. 2020;10:628. doi: 10.3390/brainsci10090628.", "ArticleIdList": ["10.3390/brainsci10090628", "PMC7564174", "32932753"]}, {"Citation": "El-Marasy S.A.A., Abd-Elsalam R.M., Ahmed-Farid O.A. Ameliorative Effect of Silymarin on Scopolamine-Induced Dementia in Rats. Open Access Maced. J. Med. Sci. 2018;6:1215\u20131224. doi: 10.3889/oamjms.2018.257.", "ArticleIdList": ["10.3889/oamjms.2018.257", "PMC6062269", "30087724"]}, {"Citation": "Duan S., Guan X., Lin R., Liu X., Yan Y., Lin R., Zhang T., Chen X., Huang J., Sun X., et al. Silibinin Inhibits Acetylcholinesterase Activity and Amyloid \u03b2 Peptide Aggregation: A Dual-Target Drug for the Treatment of Alzheimer\u2019s Disease. Neurobiol. Aging. 2015;36:1792\u20131807. doi: 10.1016/j.neurobiolaging.2015.02.002.", "ArticleIdList": ["10.1016/j.neurobiolaging.2015.02.002", "25771396"]}, {"Citation": "Yaghmaei P., Azarfar K., Dezfulian M., Ebrahim-Habibi A. Silymarin Effect on Amyloid-\u03b2 Plaque Accumulation and Gene Expression of APP in an Alzheimer\u2019s Disease Rat Model. DARU J. Pharm. Sci. 2014;22:24. doi: 10.1186/2008-2231-22-24.", "ArticleIdList": ["10.1186/2008-2231-22-24", "PMC3904165", "24460990"]}, {"Citation": "Urata N.M., Urakami K.M., Zawa Y.O., Inoshita N.K., Rie K.I., Shirasawa T., Shimizu T. Silymarin Attenuated the Amyloid \u03b2 Plaque Burden and Improved Behavioral Abnormalities in an Alzheimer\u2019s Disease Mouse Model. Biosci. Biotechnol. Biochem. 2010;74:2299\u20132306. doi: 10.1271/bbb.100524.", "ArticleIdList": ["10.1271/bbb.100524", "21071836"]}, {"Citation": "Zheng H., Koo E.H. Biology and Pathophysiology of the Amyloid Precursor Protein. Mol. Neurodegener. 2011;6:27. doi: 10.1186/1750-1326-6-27.", "ArticleIdList": ["10.1186/1750-1326-6-27", "PMC3098799", "21527012"]}, {"Citation": "Lu P., Mamiya T., Lu L.L., Mouri A., Zou L.B., Nagai T., Hiramatsu M., Ikejima T., Nabeshima T. Silibinin Prevents Amyloid b Peptide-Induced Memory Impairment and Oxidative Stress in Mice. Br. J. Pharmacol. 2009;157:1270\u20131277. doi: 10.1111/j.1476-5381.2009.00295.x.", "ArticleIdList": ["10.1111/j.1476-5381.2009.00295.x", "PMC2743846", "19552690"]}, {"Citation": "Zhou J., Chao G., Li Y.L., Wu M., Zhong S.Z., Feng Z.Y. Activation of NRF2/ARE by Isosilybin Alleviates A\u03b225-35-Induced Oxidative Stress Injury in HT-22 Cells. Neurosci. Lett. 2016;632:92\u201397. doi: 10.1016/j.neulet.2016.08.043.", "ArticleIdList": ["10.1016/j.neulet.2016.08.043", "27567700"]}, {"Citation": "Song X., Liu B., Cui L., Zhou B., Liu L., Liu W., Yao G., Xia M., Hayashi T., Hattori S., et al. Estrogen Receptors Are Involved in the Neuroprotective Effect of Silibinin in A\u03b21\u201342-Treated Rats. Neurochem. Res. 2018;43:796\u2013805. doi: 10.1007/s11064-018-2481-3.", "ArticleIdList": ["10.1007/s11064-018-2481-3", "29397533"]}, {"Citation": "Yang J., Sun Y., Xu F., Liu W., Hayashi T., Hattori S., Ushiki-Kaku Y., Onodera S., Tashiro S.I., Ikejima T. Silibinin Protects Rat Pancreatic \u03b2-Cell through up-Regulation of Estrogen Receptors\u2019 Signaling against Amylin- or A\u03b21\u201342-Induced Reactive Oxygen Species/Reactive Nitrogen Species Generation. Phyther. Res. 2019;33:998\u20131009. doi: 10.1002/ptr.6293.", "ArticleIdList": ["10.1002/ptr.6293", "30729588"]}, {"Citation": "Yard\u0131m A., Kucukler S., \u00d6zdemir S., \u00c7omakl\u0131 S., Caglayan C., Kandemir F.M., \u00c7elik H. Silymarin Alleviates Docetaxel-Induced Central and Peripheral Neurotoxicity by Reducing Oxidative Stress, Inflammation and Apoptosis in Rats. Gene. 2021;769:145239. doi: 10.1016/j.gene.2020.145239.", "ArticleIdList": ["10.1016/j.gene.2020.145239", "33069805"]}, {"Citation": "Chtourou Y., Fetoui H., Sefi M., Trabelsi K., Barkallah M., Boudawara T., Kallel H., Zeghal N. Silymarin, a Natural Antioxidant, Protects Cerebral Cortex against Manganese-Induced Neurotoxicity in Adult Rats. BioMetals. 2010;23:985\u2013996. doi: 10.1007/s10534-010-9345-x.", "ArticleIdList": ["10.1007/s10534-010-9345-x", "20503066"]}, {"Citation": "Elsawy H., Alzahrani A.M., Alfwuaires M., Sedky A., El-Trass E.E., Mahmoud O., Abdel-Moneim A.M., Khalil M. Analysis of Silymarin-Modulating Effects against Acrylamide-Induced Cerebellar Damage in Male Rats: Biochemical and Pathological Markers. J. Chem. Neuroanat. 2021;115:101964. doi: 10.1016/j.jchemneu.2021.101964.", "ArticleIdList": ["10.1016/j.jchemneu.2021.101964", "33965515"]}, {"Citation": "Hirayama K., Oshima H., Yamashita A., Sakatani K., Yoshino A., Katayama Y. Neuroprotective Effects of Silymarin on Ischemia-Induced Delayed Neuronal Cell Death in Rat Hippocampus. Brain Res. 2016;1646:297\u2013303. doi: 10.1016/j.brainres.2016.06.018.", "ArticleIdList": ["10.1016/j.brainres.2016.06.018", "27312091"]}, {"Citation": "Wang C., Wang Z., Zhang X., Zhang X., Dong L., Xing Y., Li Y., Liu Z., Chen L., Qiao H., et al. Protection by Silibinin against Experimental Ischemic Stroke: Up-Regulated PAkt, PmTOR, HIF-1\u03b1 and Bcl-2, down-Regulated Bax, NF-\u03baB Expression. Neurosci. Lett. 2012;529:45\u201350. doi: 10.1016/j.neulet.2012.08.078.", "ArticleIdList": ["10.1016/j.neulet.2012.08.078", "22999929"]}, {"Citation": "Khoshnoodi M., Fakhraei N., Dehpour A.R. Possible Involvement of Nitric Oxide in Antidepressant-like Effect of Silymarin in Male Mice. Pharm. Biol. 2015;53:739\u2013745. doi: 10.3109/13880209.2014.942787.", "ArticleIdList": ["10.3109/13880209.2014.942787", "25431050"]}, {"Citation": "Li Y.J., Li Y.J., Yang L.D., Zhang K., Zheng K.Y., Wei X.M., Yang Q., Niu W.M., Zhao M.G., Wu Y.M. Silibinin Exerts Antidepressant Effects by Improving Neurogenesis through BDNF/TrkB Pathway. Behav. Brain Res. 2018;348:184\u2013191. doi: 10.1016/j.bbr.2018.04.025.", "ArticleIdList": ["10.1016/j.bbr.2018.04.025", "29680784"]}, {"Citation": "Song X., Liu B., Cui L., Zhou B., Liu W., Xu F., Hayashi T., Hattori S., Ushiki-Kaku Y., Tashiro S.-I., et al. Silibinin Ameliorates Anxiety/Depression-like Behaviors in Amyloid \u03b2-Treated Rats by Upregulating BDNF/TrkB Pathway and Attenuating Autophagy in Hippocampus. Physiol. Behav. 2017;179:487\u2013493. doi: 10.1016/j.physbeh.2017.07.023.", "ArticleIdList": ["10.1016/j.physbeh.2017.07.023", "28735062"]}, {"Citation": "Babu H., Ramirez-Rodriguez G., Fabel K., Bischofberger J., Kempermann G. Synaptic Network Activity Induces Neuronal Differentiation of Adult Hippocampal Precursor Cells through BDNF Signaling. Front. Neurosci. 2009;1:1\u201311. doi: 10.3389/neuro.22.001.2009.", "ArticleIdList": ["10.3389/neuro.22.001.2009", "PMC2858558", "20582276"]}, {"Citation": "Park H., Poo M.M. Neurotrophin Regulation of Neural Circuit Development and Function. Nat. Rev. Neurosci. 2013;14:7\u201323. doi: 10.1038/nrn3379.", "ArticleIdList": ["10.1038/nrn3379", "23254191"]}, {"Citation": "Raza S.S., Khan M.M., Ashafaq M., Ahmad A., Khuwaja G., Khan A., Siddiqui M.S., Safhi M.M., Islam F. Silymarin Protects Neurons from Oxidative Stress Associated Damages in Focal Cerebral Ischemia: A Behavioral, Biochemical and Immunohistological Study in Wistar Rats. J. Neurol. Sci. 2011;309:45\u201354. doi: 10.1016/j.jns.2011.07.035.", "ArticleIdList": ["10.1016/j.jns.2011.07.035", "21840019"]}, {"Citation": "Wang M., Li Y.J., Ding Y., Zhang H.N., Sun T., Zhang K., Yang L., Guo Y.Y., Liu S.B., Zhao M.G., et al. Silibinin Prevents Autophagic Cell Death upon Oxidative Stress in Cortical Neurons and Cerebral Ischemia-Reperfusion Injury. Mol. Neurobiol. 2016;53:932\u2013943. doi: 10.1007/s12035-014-9062-5.", "ArticleIdList": ["10.1007/s12035-014-9062-5", "25561437"]}, {"Citation": "Al-Rasheed N.M., Al-Rasheed N.M., Faddah L.M., Mohamed A.M., Mohammad R.A., Al-Amin M. Potential Impact of Silymarin in Combination with Chlorogenic Acid and/or Melatonin in Combating Cardiomyopathy Induced by Carbon Tetrachloride. Saudi J. Biol. Sci. 2014;21:265\u2013274. doi: 10.1016/j.sjbs.2013.09.006.", "ArticleIdList": ["10.1016/j.sjbs.2013.09.006", "PMC4061402", "24955012"]}, {"Citation": "Rao P.R., Viswanath R.K. Cardioprotective Activity of Silymarin in Ischemia-Reperfusion-Induced Myocardial Infarction in Albino Rats. Exp. Clin. Cardiol. 2007;12:179\u2013187.", "ArticleIdList": ["PMC2359609", "18651002"]}, {"Citation": "Taghiabadi E., Imenshahidi M., Abnous K., Mosafa F., Sankian M., Memar B., Karimi G. Protective Effect of Silymarin against Acrolein-Induced Cardiotoxicity in Mice. Evid.-Based Complement. Altern. Med. 2012;2012:1\u201314. doi: 10.1155/2012/352091.", "ArticleIdList": ["10.1155/2012/352091", "PMC3535759", "23320028"]}, {"Citation": "Gabrielov\u00e1 E., Zholobenko A.V., Barto\u0161\u00edkov\u00e1 L., Ne\u010das J., Modriansky M. Silymarin Constituent 2,3-Dehydrosilybin Triggers Reserpine-Sensitive Positive Inotropic Effect in Perfused Rat Heart. PLoS ONE. 2015;10:e0139208. doi: 10.1371/journal.pone.0139208.", "ArticleIdList": ["10.1371/journal.pone.0139208", "PMC4856230", "26418338"]}, {"Citation": "Jadhav G.B., Upasani C.D. Antihypertensive Effect of Silymarin on DOCA Salt Induced Hypertension in Unilateral Nephrectomized Rats. Orient. Pharm. Exp. Med. 2011;11:101\u2013106. doi: 10.1007/s13596-011-0018-2.", "ArticleIdList": ["10.1007/s13596-011-0018-2"]}, {"Citation": "Jadhav G.B., Upasani C.D. Antihypertensive Effect of Silymarin on Fructose Induced Hypertensive Rats. Indian J. Pharm. Educ. Res. 2012;46:26."}, {"Citation": "Ahmed-Belkacem A., Ahnou N., Barbotte L., Wychowski C., Pallier C., Brillet R., Pohl R.T., Pawlotsky J.M. Silibinin and Related Compounds Are Direct Inhibitors of Hepatitis C Virus RNA-Dependent RNA Polymerase. Gastroenterology. 2010;138:1112\u20131122. doi: 10.1053/j.gastro.2009.11.053.", "ArticleIdList": ["10.1053/j.gastro.2009.11.053", "19962982"]}, {"Citation": "Wagoner J., Negash A., Kane O.J., Martinez L.E., Nahmias Y., Bourne N., Owen D.M., Grove J., Brimacombe C., McKeating J.A., et al. Multiple Effects of Silymarin on the Hepatitis C Virus Lifecycle. Hepatology. 2010;51:1912\u20131921. doi: 10.1002/hep.23587.", "ArticleIdList": ["10.1002/hep.23587", "PMC2909978", "20512985"]}, {"Citation": "Anthony K., Subramanya G., Uprichard S., Hammouda F., Saleh M. Antioxidant and Anti-Hepatitis C Viral Activities of Commercial Milk Thistle Food Supplements. Antioxidants. 2013;2:23\u201336. doi: 10.3390/antiox2010023.", "ArticleIdList": ["10.3390/antiox2010023", "PMC4665399", "26787620"]}, {"Citation": "Ferenci P., Scherzer T.M., Kerschner H., Rutter K., Beinhardt S., Hofer H., Sch\u00f6niger-Hekele M., Holzmann H., Steindl-Munda P. Silibinin Is a Potent Antiviral Agent in Patients with Chronic Hepatitis C Not Responding to Pegylated Interferon/Ribavirin Therapy. Gastroenterology. 2008;135:1561\u20131567. doi: 10.1053/j.gastro.2008.07.072.", "ArticleIdList": ["10.1053/j.gastro.2008.07.072", "18771667"]}, {"Citation": "Sabir S., Arshad M., Asif S., Chaudhari S.K. An Insight into Medicinal and Therapeutic Potential of Silybum marianum (L.) Gaertn. Int. J. Biosci. 2014;4:104\u2013115. doi: 10.12692/ijb/4.11.104-115.", "ArticleIdList": ["10.12692/ijb/4.11.104-115"]}, {"Citation": "Saller R., Meier R., Brignoli R. The Use of Silymarin in the Treatment of Liver Diseases. Drugs. 2001;61:2035\u20132063. doi: 10.2165/00003495-200161140-00003.", "ArticleIdList": ["10.2165/00003495-200161140-00003", "11735632"]}, {"Citation": "Polyak S.J., Morishima C., Shuhart M.C., Wang C.C., Liu Y., Lee D.Y.W. Inhibition of T-Cell Inflammatory Cytokines, Hepatocyte NF-\u03baB Signaling, and HCV Infection by Standardized Silymarin. Gastroenterology. 2007;132:1925\u20131936. doi: 10.1053/j.gastro.2007.02.038.", "ArticleIdList": ["10.1053/j.gastro.2007.02.038", "17484885"]}, {"Citation": "DebRoy S., Hiraga N., Imamura M., Hayes C.N., Akamatsu S., Canini L., Perelson A.S., Pohl R.T., Persiani S., Uprichard S.L., et al. Hepatitis C Virus Dynamics and Cellular Gene Expression in UPA-SCID Chimeric Mice with Humanized Livers during Intravenous Silibinin Monotherapy. J. Viral Hepat. 2016;23:708\u2013717. doi: 10.1111/jvh.12551.", "ArticleIdList": ["10.1111/jvh.12551", "PMC4974116", "27272497"]}, {"Citation": "Blaising J., L\u00e9vy P.L., Gondeau C., Phelip C., Varbanov M., Teissier E., Ruggiero F., Polyak S.J., Oberlies N.H., Ivanovic T., et al. Silibinin Inhibits Hepatitis C Virus Entry into Hepatocytes by Hindering Clathrin-Dependent Trafficking. Cell. Microbiol. 2013;15:1866\u20131882. doi: 10.1111/cmi.12155.", "ArticleIdList": ["10.1111/cmi.12155", "23701235"]}, {"Citation": "Malaguarnera G., Bertino G., Chisari G., Motta M., Vecchio M., Vacante M., Caraci F., Greco C., Drago F., Nunnari G., et al. Silybin Supplementation during HCV Therapy with Pegylated Interferon-\u03b1 plus Ribavirin Reduces Depression and Anxiety and Increases Work Ability. BMC Psychiatry. 2016;16:398. doi: 10.1186/s12888-016-1115-z.", "ArticleIdList": ["10.1186/s12888-016-1115-z", "PMC5109776", "27842532"]}, {"Citation": "Malaguarnera M., Motta M., Vacante M., Malaguarnera G., Caraci F., Nunnari G., Gagliano C., Greco C., Chisari G., Drago F., et al. Silybin-Vitamin E-Phospholipids Complex Reduces Liver Fibrosis in Patients with Chronic Hepatitis C Treated with Pegylated Interferon \u03b1 and Ribavirin. Am. J. Transl. Res. 2015;7:2510\u20132518.", "ArticleIdList": ["PMC4697727", "26807195"]}, {"Citation": "Biermer M., Berg T. Rapid Suppression of Hepatitis C Viremia Induced by Intravenous Silibinin plus Ribavirin. Gastroenterology. 2009;137:390\u2013391. doi: 10.1053/j.gastro.2009.02.087.", "ArticleIdList": ["10.1053/j.gastro.2009.02.087", "19486953"]}, {"Citation": "Mari\u00f1o Z., Crespo G., D\u2019Amato M., Brambilla N., Giacovelli G., Rovati L., Costa J., Navasa M., Forns X. Intravenous Silibinin Monotherapy Shows Significant Antiviral Activity in HCV-Infected Patients in the Peri-Transplantation Period. J. Hepatol. 2013;58:415\u2013420. doi: 10.1016/j.jhep.2012.09.034.", "ArticleIdList": ["10.1016/j.jhep.2012.09.034", "23063567"]}, {"Citation": "B\u00e1rcena R., Moreno A., Rodr\u00edguez-Gand\u00eda M.A., Albillos A., Arocena C., Blesa C., Garc\u00eda-Hoz F., Graus J., Nu\u00f1o J., L\u00f3pez-Herv\u00e1s P., et al. Safety and Anti-HCV Effect of Prolonged Intravenous Silibinin in HCV Genotype 1 Subjects in the Immediate Liver Transplant Period. J. Hepatol. 2013;58:421\u2013426. doi: 10.1016/j.jhep.2012.10.009.", "ArticleIdList": ["10.1016/j.jhep.2012.10.009", "23073223"]}, {"Citation": "Umetsu T., Inoue J., Kogure T., Kakazu E., Ninomiya M., Iwata T., Takai S., Nakamura T., Sano A., Shimosegawa T. Inhibitory Effect of Silibinin on Hepatitis B Virus Entry. Biochem. Biophys. Rep. 2018;14:20\u201325. doi: 10.1016/j.bbrep.2018.03.003.", "ArticleIdList": ["10.1016/j.bbrep.2018.03.003", "PMC5986624", "29872730"]}, {"Citation": "Speciale A., Muscar\u00e0 C., Molonia M.S., Cimino F., Saija A., Giofr\u00e8 S.V. Silibinin as Potential Tool against SARS-CoV-2: In Silico Spike Receptor-Binding Domain and Main Protease Molecular Docking Analysis, and In Vitro Endothelial Protective Effects. Phyther. Res. 2021;35:4616\u20134625. doi: 10.1002/ptr.7107.", "ArticleIdList": ["10.1002/ptr.7107", "PMC8251480", "33822421"]}, {"Citation": "Song J.H., Choi H.J. Silymarin Efficacy against Influenza A Virus Replication. Phytomedicine. 2011;18:832\u2013835. doi: 10.1016/j.phymed.2011.01.026.", "ArticleIdList": ["10.1016/j.phymed.2011.01.026", "21377857"]}, {"Citation": "Dai J.P., Wu L.Q., Li R., Zhao X.F., Wan Q.Y., Chen X.X., Li W.Z., Wang G.F., Li K.S. Identification of 23-(S)-2-Amino-3-Phenylpropanoyl-Silybin as an Antiviral Agent for Influenza A Virus Infection In Vitro and In Vivo. Antimicrob. Agents Chemother. 2013;57:4433\u20134443. doi: 10.1128/AAC.00759-13.", "ArticleIdList": ["10.1128/AAC.00759-13", "PMC3754338", "23836164"]}, {"Citation": "Qaddir I., Rasool N., Hussain W., Mahmood S. Computer-Aided Analysis of Phytochemicals as Potential Dengue Virus Inhibitors Based on Molecular Docking, ADMET and DFT Studies. J. Vector Borne Dis. 2017;54:255\u2013262. doi: 10.4103/0972-9062.217617.", "ArticleIdList": ["10.4103/0972-9062.217617", "29097641"]}, {"Citation": "Low Z.X., OuYong B.M., Hassandarvish P., Poh C.L., Ramanathan B. Antiviral Activity of Silymarin and Baicalein against Dengue Virus. Sci. Rep. 2021;11:21221. doi: 10.1038/s41598-021-98949-y.", "ArticleIdList": ["10.1038/s41598-021-98949-y", "PMC8551334", "34707245"]}, {"Citation": "Camini F.C., da Silva T.F., da Silva Caetano C.C., Almeida L.T., Ferraz A.C., Alves Vitoreti V.M., de Mello Silva B., de Queiroz Silva S., de Magalh\u00e3es J.C., de Brito Magalh\u00e3es C.L. Antiviral Activity of Silymarin against Mayaro Virus and Protective Effect in Virus-Induced Oxidative Stress. Antivir. Res. 2018;158:8\u201312. doi: 10.1016/j.antiviral.2018.07.023.", "ArticleIdList": ["10.1016/j.antiviral.2018.07.023", "30076863"]}, {"Citation": "Ferraz A.C., Almeida L.T., da Silva Caetano C.C., da Silva Menegatto M.B., Souza Lima R.L., de Senna J.P.N., de Oliveira Cardoso J.M., Perucci L.O., Talvani A., Geraldo de Lima W., et al. Hepatoprotective, Antioxidant, Anti-Inflammatory, and Antiviral Activities of Silymarin against Mayaro Virus Infection. Antivir. Res. 2021;194:105168. doi: 10.1016/j.antiviral.2021.105168.", "ArticleIdList": ["10.1016/j.antiviral.2021.105168", "34437912"]}, {"Citation": "Lalani S.S., Anasir M.I., Poh C.L. Antiviral Activity of Silymarin in Comparison with Baicalein against EV-A71. BMC Complement. Med. Ther. 2020;20:97. doi: 10.1186/s12906-020-2880-2.", "ArticleIdList": ["10.1186/s12906-020-2880-2", "PMC7092479", "32293397"]}, {"Citation": "Lani R., Hassandarvish P., Chiam C.W., Moghaddam E., Chu J.J.H., Rausalu K., Merits A., Higgs S., Vanlandingham D., Abu Bakar S., et al. Antiviral Activity of Silymarin against Chikungunya Virus. Sci. Rep. 2015;5:11421. doi: 10.1038/srep11421.", "ArticleIdList": ["10.1038/srep11421", "PMC4468427", "26078201"]}, {"Citation": "Lani R., Agharbaoui F.E., Hassandarvish P., Teoh B.T., Sam S.S., Zandi K., Rahman N.A., Abubakar S. In Silico Studies of Fisetin and Silymarin as Novel Chikungunya Virus Nonstructural Proteins Inhibitors. Future Virol. 2021;16:167\u2013180. doi: 10.2217/fvl-2019-0090.", "ArticleIdList": ["10.2217/fvl-2019-0090"]}, {"Citation": "Cardile A.P., Mbuy G.K.N. Anti-Herpes Virus Activity of Silibinin, the Primary Active Component of Silybum marianum. J. Herb. Med. 2013;3:132\u2013136. doi: 10.1016/j.hermed.2013.07.002.", "ArticleIdList": ["10.1016/j.hermed.2013.07.002"]}, {"Citation": "McClure J., Lovelace E.S., Elahi S., Maurice N.J., Wagoner J., Dragavon J., Mittler J.E., Kraft Z., Stamatatos L., Horton H., et al. Silibinin Inhibits HIV-1 Infection by Reducing Cellular Activation and Proliferation. PLoS ONE. 2012;7:41832. doi: 10.1371/annotation/78ba072a-6b7a-430a-8fcd-ef020e4fc458.", "ArticleIdList": ["10.1371/annotation/78ba072a-6b7a-430a-8fcd-ef020e4fc458", "PMC3404953", "22848626"]}, {"Citation": "McClure J., Margineantu D.H., Sweet I.R., Polyak S.J. Inhibition of HIV by Legalon-SIL Is Independent of Its Effect on Cellular Metabolism. Virology. 2014;449:96\u2013103. doi: 10.1016/j.virol.2013.11.003.", "ArticleIdList": ["10.1016/j.virol.2013.11.003", "PMC3909448", "24418542"]}, {"Citation": "Zhou B., Wu L.J., Li N.H., Tashiro S.I., Onodera S., Uchiumi F., Ikejima T. Silibinin Protects against Isoproterenol-Induced Rat Cardiac Myocyte Injury through Mitochondrial Pathway after up-Regulation of SIRT1. J. Pharmacol. Sci. 2006;102:387\u2013395. doi: 10.1254/jphs.FPJ06005X.", "ArticleIdList": ["10.1254/jphs.FPJ06005X", "17170512"]}, {"Citation": "Ra\u0161kovi\u0107 A., Stilinovi\u0107 N., Kolarovi\u0107 J., Vasovi\u0107 V., Vukmirovi\u0107 S., Mikov M. The Protective Effects of Silymarin against Doxorubicin-Induced Cardiotoxicity and Hepatotoxicity in Rats. Molecules. 2011;16:8601\u20138613. doi: 10.3390/molecules16108601.", "ArticleIdList": ["10.3390/molecules16108601", "PMC6264541", "21993249"]}, {"Citation": "Esser-Nobis K., Romero-Brey I., Ganten T.M., Gouttenoire J., Harak C., Klein R., Schemmer P., Binder M., Schnitzler P., Moradpour D., et al. Analysis of Hepatitis C Virus Resistance to Silibinin In Vitro and In Vivo Points to a Novel Mechanism Involving Nonstructural Protein 4B. Hepatology. 2013;57:953\u2013963. doi: 10.1002/hep.26260.", "ArticleIdList": ["10.1002/hep.26260", "PMC3593759", "23322644"]}, {"Citation": "Sardanelli A.M., Isgr\u00f2 C., Palese L.L. SARS-CoV-2 Main Protease Active Site Ligands in the Human Metabolome. Molecules. 2021;26:1409. doi: 10.3390/molecules26051409.", "ArticleIdList": ["10.3390/molecules26051409", "PMC7961382", "33807773"]}, {"Citation": "Payer B.A., Reiberger T., Rutter K., Beinhardt S., Staettermayer A.F., Peck-Radosavljevic M., Ferenci P. Successful HCV Eradication and Inhibition of HIV Replication by Intravenous Silibinin in an HIV-HCV Coinfected Patient. J. Clin. Virol. 2010;49:131\u2013133. doi: 10.1016/j.jcv.2010.07.006.", "ArticleIdList": ["10.1016/j.jcv.2010.07.006", "20709593"]}, {"Citation": "Braun D., Rauch A., Durisch N., Eberhard N., Anagnostopoulos A., Ledergerber B., Metzner K., B\u00f6ni J., Weber R., Fehr J. Efficacy of Lead-in Silibinin and Subsequent Triple Therapy in Difficult-to-Treat HIV/Hepatitis C Virus-Coinfected Patients. HIV Med. 2014;15:625\u2013630. doi: 10.1111/hiv.12166.", "ArticleIdList": ["10.1111/hiv.12166", "24894776"]}, {"Citation": "Braun D.L., Rauch A., Aouri M., Durisch N., Eberhard N., Anagnostopoulos A., Ledergerber B., M\u00f6llhaupt B., Metzner K.J., Decosterd L., et al. A Lead-in with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-to-Treat HIV/Hepatitis C Coinfected Patients. PLoS ONE. 2015;10:e0133028. doi: 10.1371/journal.pone.0133028.", "ArticleIdList": ["10.1371/journal.pone.0133028", "PMC4503454", "26176696"]}, {"Citation": "Bosch-Barrera J., Martin-Castillo B., Bux\u00f3 M., Brunet J., Encinar J.A., Menendez J.A. Silibinin and SARS-CoV-2: Dual Targeting of Host Cytokine Storm and Virus Replication Machinery for Clinical Management of COVID-19 Patients. J. Clin. Med. 2020;9:1770. doi: 10.3390/jcm9061770.", "ArticleIdList": ["10.3390/jcm9061770", "PMC7356916", "32517353"]}, {"Citation": "Gorla U.S., Rao K., Kulandaivelu U.S., Alavala R.R., Panda S.P. Lead Finding from Selected Flavonoids with Antiviral (SARS-CoV-2) Potentials against COVID-19: An In-Silico Evaluation. Comb. Chem. High Throughput Screen. 2020;24:879\u2013890. doi: 10.2174/1386207323999200818162706.", "ArticleIdList": ["10.2174/1386207323999200818162706", "32819226"]}, {"Citation": "Boer M., Duchnik E., Maleszka R., Marchlewicz M. Structural and Biophysical Characteristics of Human Skin in Maintaining Proper Epidermal Barrier Function. Postep. Dermatol. Alergol. 2016;33:1\u20135. doi: 10.5114/pdia.2015.48037.", "ArticleIdList": ["10.5114/pdia.2015.48037", "PMC4793052", "26985171"]}, {"Citation": "Benson H.A.E., Grice J.E., Mohammed Y., Namjoshi S., Roberts M.S. Topical and Transdermal Drug Delivery: From Simple Potions to Smart Technologies. Curr. Drug Deliv. 2019;16:444\u2013460. doi: 10.2174/1567201816666190201143457.", "ArticleIdList": ["10.2174/1567201816666190201143457", "PMC6637104", "30714524"]}, {"Citation": "Svobodov\u00e1 A., Vost\u00e1lov\u00e1 J. Solar Radiation Induced Skin Damage: Review of Protective and Preventive Options. Int. J. Radiat. Biol. 2010;86:999\u20131030. doi: 10.3109/09553002.2010.501842.", "ArticleIdList": ["10.3109/09553002.2010.501842", "20807180"]}, {"Citation": "Guillermo-Lagae R., Deep G., Ting H., Agarwal C., Agarwal R. Silibinin Enhances the Repair of Ultraviolet B-Induced DNA Damage by Activating P53-Dependent Nucleotide Excision Repair Mechanism in Human Dermal Fibroblasts. Oncotarget. 2015;6:39594\u201339606. doi: 10.18632/oncotarget.5519.", "ArticleIdList": ["10.18632/oncotarget.5519", "PMC4741848", "26447614"]}, {"Citation": "Katiyar S.K., Mantena S.K., Meeran S.M. Silymarin Protects Epidermal Keratinocytes from Ultraviolet Radiation-Induced Apoptosis and DNA Damage by Nucleotide Excision Repair Mechanism. PLoS ONE. 2011;6:e21410. doi: 10.1371/journal.pone.0021410.", "ArticleIdList": ["10.1371/journal.pone.0021410", "PMC3120878", "21731736"]}, {"Citation": "Roy S., Deep G., Agarwal C., Agarwal R. Silibinin Prevents Ultraviolet B Radiation-Induced Epidermal Damages in JB6 Cells and Mouse Skin in a P53-GADD45\u03b1-Dependent Manner. Carcinogenesis. 2012;33:629\u2013636. doi: 10.1093/carcin/bgr299.", "ArticleIdList": ["10.1093/carcin/bgr299", "PMC3384068", "22166495"]}, {"Citation": "Rigby C.M., Roy S., Deep G., Guillermo-Lagae R., Jain A.K., Dhar D., Orlicky D.J., Agarwal C., Agarwal R. Role of P53 in Silibinin-Mediated Inhibition of Ultraviolet B Radiation-Induced DNA Damage, Inflammation and Skin Carcinogenesis. Carcinogenesis. 2017;38:40\u201350. doi: 10.1093/carcin/bgw106.", "ArticleIdList": ["10.1093/carcin/bgw106", "PMC5219048", "27729375"]}, {"Citation": "Carrier F., Georgel P.T., Pourquier P., Blake M., Kontny H.U., Antinore M.J., Gariboldi M., Myers T.G., Weinstein J.N., Pommier Y., et al. Gadd45, a P53-Responsive Stress Protein, Modifies DNA Accessibility on Damaged Chromatin. Mol. Cell. Biol. 1999;19:1673\u20131685. doi: 10.1128/MCB.19.3.1673.", "ArticleIdList": ["10.1128/MCB.19.3.1673", "PMC83961", "10022855"]}, {"Citation": "Yang X., Zhu L., Zhao W., He C., Li S., Xu C. GADD45\u03b1 Regulates Cell Proliferation and DNA Repair of BRL-3A Cells That Treated by FZD/UVC via P38, JNK, CDC2/CCNB1, AKT and MTOR Pathways. bioRxiv. 2017:148759. doi: 10.1101/148759.", "ArticleIdList": ["10.1101/148759"]}, {"Citation": "Gu M., Dhanalakshmi S., Mohan S., Singh R.P., Agarwal R. Silibinin Inhibits Ultraviolet B Radiation-Induced Mitogenic and Survival Signaling, and Associated Biological Responses in SKH-1 Mouse Skin. Carcinogenesis. 2005;26:1404\u20131413. doi: 10.1093/carcin/bgi096.", "ArticleIdList": ["10.1093/carcin/bgi096", "15831527"]}, {"Citation": "Rajnochov\u00e1 Svobodov\u00e1 A., Gabrielov\u00e1 E., Ulrichov\u00e1 J., Z\u00e1le\u0161\u00e1k B., Biedermann D., Vost\u00e1lov\u00e1 J. A Pilot Study of the UVA-Photoprotective Potential of Dehydrosilybin, Isosilybin, Silychristin, and Silydianin on Human Dermal Fibroblasts. Arch. Dermatol. Res. 2019;311:477\u2013490. doi: 10.1007/s00403-019-01928-7.", "ArticleIdList": ["10.1007/s00403-019-01928-7", "31079190"]}, {"Citation": "Rajnochov\u00e1 Svobodov\u00e1 A., Gabrielov\u00e1 E., Michaelides L., Kosina P., Ry\u0161av\u00e1 A., Ulrichov\u00e1 J., Z\u00e1le\u0161\u00e1k B., Vost\u00e1lov\u00e1 J. UVA-Photoprotective Potential of Silymarin and Silybin. Arch. Dermatol. Res. 2018;310:413\u2013424. doi: 10.1007/s00403-018-1828-6.", "ArticleIdList": ["10.1007/s00403-018-1828-6", "29564550"]}, {"Citation": "Katiyar S.K., Meleth S., Sharma S.D. Silymarin, a Flavonoid from Milk Thistle (Silybum marianum L.), Inhibits UV-Induced Oxidative Stress through Targeting Infiltrating CD11b+ Cells in Mouse Skin. Photochem. Photobiol. 2008;84:266\u2013271. doi: 10.1111/j.1751-1097.2007.00241.x.", "ArticleIdList": ["10.1111/j.1751-1097.2007.00241.x", "PMC2394725", "18221354"]}, {"Citation": "Svobodov\u00e1 A., Zda\u0159ilov\u00e1 A., Walterov\u00e1 D., Vost\u00e1lov\u00e1 J. Flavonolignans from Silybum marianum Moderate UVA-Induced Oxidative Damage to HaCaT Keratinocytes. J. Dermatol. Sci. 2007;48:213\u2013224. doi: 10.1016/j.jdermsci.2007.06.008.", "ArticleIdList": ["10.1016/j.jdermsci.2007.06.008", "17689055"]}, {"Citation": "Svobodov\u00e1 A., Zda\u0159ilov\u00e1 A., Mali\u0161kov\u00e1 J., Mikulkov\u00e1 H., Walterov\u00e1 D., Vostalov\u00e1 J. Attenuation of UVA-Induced Damage to Human Keratinocytes by Silymarin. J. Dermatol. Sci. 2007;46:21\u201330. doi: 10.1016/j.jdermsci.2006.12.009.", "ArticleIdList": ["10.1016/j.jdermsci.2006.12.009", "17289350"]}, {"Citation": "Li L.H., Wu L., Tashiro S., Onodera S., Uchiumi F., Ikejima T. Activation of the SIRT1 Pathway and Modulation of the Cell Cycle Were Involved in Silymarin\u2019s Protection against UV-Induced A375-S2 Cell Apoptosis. J. Asian Nat. Prod. Res. 2007;9:245\u2013252. doi: 10.1080/10286020600604260.", "ArticleIdList": ["10.1080/10286020600604260", "17566917"]}, {"Citation": "Jur\u00e1\u0148ov\u00e1 J., Aury-Landas J., Boumediene K., Baug\u00e9 C., Biedermann D., Ulrichov\u00e1 J., Frankov\u00e1 J. Modulation of Skin Inflammatory Response by Active Components of Silymarin. Molecules. 2019;24:123. doi: 10.3390/molecules24010123.", "ArticleIdList": ["10.3390/molecules24010123", "PMC6337225", "30598040"]}, {"Citation": "Li L.H., Wu L.J., Tashiro S.I., Onodera S., Uchiumi F., Ikejima T. Silibinin Prevents UV-Induced HaCaT Cell Apoptosis Partly through Inhibition of Caspase-8 Pathway. Biol. Pharm. Bull. 2006;29:1096\u20131101. doi: 10.1248/bpb.29.1096.", "ArticleIdList": ["10.1248/bpb.29.1096", "16755000"]}, {"Citation": "Narayanapillai S., Agarwal C., Tilley C., Agarwal R. Proceedings of the Photochemistry and Photobiology. Volume 88. John Wiley & Sons, Ltd.; Hoboken, NJ, USA: 2012. Silibinin Is a Potent Sensitizer of UVA Radiation-Induced Oxidative Stress and Apoptosis in Human Keratinocyte HaCaT Cells; pp. 1135\u20131140.", "ArticleIdList": ["PMC3925450", "22118157"]}, {"Citation": "Altaei T. The Treatment of Melasma by Silymarin Cream. BMC Dermatol. 2012;12:18. doi: 10.1186/1471-5945-12-18.", "ArticleIdList": ["10.1186/1471-5945-12-18", "PMC3519762", "23031632"]}, {"Citation": "Cheon H.I., Bae S., Ahn K.J. Flavonoid Silibinin Increases Hair-Inductive Property via Akt and Wnt/\u03b2-Catenin Signaling Activation in 3-Dimensional-Spheroid Cultured Human Dermal Papilla Cells. J. Microbiol. Biotechnol. 2019;29:321\u2013329. doi: 10.4014/jmb.1810.10050.", "ArticleIdList": ["10.4014/jmb.1810.10050", "30609881"]}, {"Citation": "Sharifi R., Pasalar P., Kamalinejad M., Dehpour A.R., Tavangar S.M., Paknejad M., Mehrabani Natanzi M., Nourbakhsh M., Ahmadi Ashtiani H.R., Akbari M., et al. The Effect of Silymarin (Silybum marianum) on Human Skin Fibroblasts in an In Vitro Wound Healing Model. Pharm. Biol. 2013;51:298\u2013303. doi: 10.3109/13880209.2012.721789.", "ArticleIdList": ["10.3109/13880209.2012.721789", "23137300"]}, {"Citation": "Tabari S.A., Carpi S., Polini B., Nieri P., Esfahani M.L., Moghadamnia A.A., Ghorbani H., Ranaei M., Kazemi S. Topical Application of Silymarin Enhances Cutaneous Wound Healing in Rats. South African J. Bot. 2019;124:494\u2013498. doi: 10.1016/j.sajb.2019.06.004.", "ArticleIdList": ["10.1016/j.sajb.2019.06.004"]}, {"Citation": "Oryan A., Tabatabaei Naeini A., Moshiri A., Mohammadalipour A., Tabandeh M.R. Modulation of Cutaneous Wound Healing by Silymarin in Rats. J. Wound Care. 2012;21:457\u2013464. doi: 10.12968/jowc.2012.21.9.457.", "ArticleIdList": ["10.12968/jowc.2012.21.9.457", "22990400"]}, {"Citation": "Vost\u00e1lov\u00e1 J., Tinkov\u00e1 E., Biedermann D., Kosina P., Ulrichov\u00e1 J., Svobodov\u00e1 A.R. Skin Protective Activity of Silymarin and Its Flavonolignans. Molecules. 2019;24:1022. doi: 10.3390/molecules24061022.", "ArticleIdList": ["10.3390/molecules24061022", "PMC6470681", "30875758"]}, {"Citation": "Ebrahimpour Koujan S., Gargari B.P., Mobasseri M., Valizadeh H., Asghari-Jafarabadi M. Effects of Silybum marianum (L.) Gaertn. (Silymarin) Extract Supplementation on Antioxidant Status and Hs-CRP in Patients with Type 2 Diabetes Mellitus: A Randomized, Triple-Blind, Placebo-Controlled Clinical Trial. Phytomedicine. 2015;22:290\u2013296. doi: 10.1016/j.phymed.2014.12.010.", "ArticleIdList": ["10.1016/j.phymed.2014.12.010", "25765835"]}, {"Citation": "Ebrahimpour-koujan S., Gargari B.P., Mobasseri M., Valizadeh H., Asghari-Jafarabadi M. Lower Glycemic Indices and Lipid Profile among Type 2 Diabetes Mellitus Patients Who Received Novel Dose of Silybum marianum (L.) Gaertn. (Silymarin) Extract Supplement: A Triple-Blinded Randomized Controlled Clinical Trial. Phytomedicine. 2018;44:39\u201344. doi: 10.1016/j.phymed.2018.03.050.", "ArticleIdList": ["10.1016/j.phymed.2018.03.050", "29895491"]}, {"Citation": "Derosa G., D\u2019Angelo A., Maffioli P. The Role of a Fixed Berberis Aristata/Silybum marianum Combination in the Treatment of Type 1 Diabetes Mellitus. Clin. Nutr. 2016;35:1091\u20131095. doi: 10.1016/j.clnu.2015.08.004.", "ArticleIdList": ["10.1016/j.clnu.2015.08.004", "26384091"]}, {"Citation": "Di Pierro F., Putignano P., Villanova N., Montesi L., Moscatiello S., Marchesini G. Preliminary Study about the Possible Glycemic Clinical Advantage in Using a Fixed Combination of Berberis Aristata and Silybum marianum Standardized Extracts versus Only Berberis Aristata in Patients with Type 2 Diabetes. Clin. Pharmacol. Adv. Appl. 2013;5:167\u2013174. doi: 10.2147/CPAA.S54308.", "ArticleIdList": ["10.2147/CPAA.S54308", "PMC3838471", "24277991"]}, {"Citation": "Hahn H.J., Jung H.J., Schrammek-Drusios M.C., Lee S.N., Kim J.H., Kwon S.B., An I.S., An S., Ahn K.J. Instrumental Evaluation of Anti-Aging Effects of Cosmetic Formulations Containing Palmitoyl Peptides, Silybum marianum Seed Oil, Vitamin E and Other Functional Ingredients on Aged Human Skin. Exp. Ther. Med. 2016;12:1171\u20131176. doi: 10.3892/etm.2016.3447.", "ArticleIdList": ["10.3892/etm.2016.3447", "PMC4950680", "27446338"]}, {"Citation": "AlAnbari H., Sahib A., Raghif A. Effects of Silymarin, N-Acetylcysteine and Selenium in the Treatment of Papulopustular Acne. Oxid. Antioxid. Med. Sci. 2012;1:201\u2013207. doi: 10.5455/oams.290912.or.019.", "ArticleIdList": ["10.5455/oams.290912.or.019"]}, {"Citation": "Curcio A., Romano A., Cuozzo S., Di Nicola A., Grassi O., Schiaroli D., Nocera G.F., Pironti M. Silymarin in Combination with Vitamin C, Vitamin E, Coenzyme Q10 and Selenomethionine to Improve Liver Enzymes and Blood Lipid Profile in NAFLD Patients. Medicina. 2020;56:544. doi: 10.3390/medicina56100544.", "ArticleIdList": ["10.3390/medicina56100544", "PMC7603183", "33080906"]}, {"Citation": "Hajiaghamohammadi A.A., Ziaee A., Oveisi S., Masroor H. Effects of Metformin, Pioglitazone, and Silymarin Treatment on Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Pilot Study. Hepat. Mon. 2012;12:6099. doi: 10.5812/hepatmon.6099.", "ArticleIdList": ["10.5812/hepatmon.6099", "PMC3475019", "23087748"]}, {"Citation": "Aller R., Izaola O., G\u00f3mez S., Tafur C., Gonz\u00e1lez G., Berroa E., Mora N., Gonz\u00e1lez J.M., De Luis D.A. Effect of Silymarin plus Vitamin E in Patients with Non-Alcoholic Fatty Liver Disease. A Randomized Clinical Pilot Study. Eur. Rev. Med. Pharmacol. Sci. 2015;19:3118\u20133124.", "ArticleIdList": ["26367736"]}, {"Citation": "Abenavoli L., Greco M., Nazionale I., Peta V., Milic N., Accattato F., Foti D., Gulletta E., Luzza F. Effects of Mediterranean Diet Supplemented with Silybin-Vitamin E-Phospholipid Complex in Overweight Patients with Non-Alcoholic Fatty Liver Disease. Expert Rev. Gastroenterol. Hepatol. 2015;9:519\u2013527. doi: 10.1586/17474124.2015.1004312.", "ArticleIdList": ["10.1586/17474124.2015.1004312", "25617046"]}, {"Citation": "Federico A., Dallio M., Gravina A.G., Diano N., Errico S., Masarone M., Romeo M., Tuccillo C., Stiuso P., Morisco F., et al. The Bisphenol a Induced Oxidative Stress in Non-Alcoholic Fatty Liver Disease Male Patients: A Clinical Strategy to Antagonize the Progression of the Disease. Int. J. Environ. Res. Public Health. 2020;17:3369. doi: 10.3390/ijerph17103369.", "ArticleIdList": ["10.3390/ijerph17103369", "PMC7277712", "32408667"]}, {"Citation": "Solhi H., Ghahremani R., Kazemifar A.M., Yazdi Z.H. Silymarin in Treatment of Non-Alcoholic Steatohepatitis: A Randomized Clinical Trial. Casp. J. Intern. Med. 2014;5:9\u201312.", "ArticleIdList": ["PMC3894463", "24490006"]}, {"Citation": "Wah Kheong C., Nik Mustapha N.R., Mahadeva S. A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis. Clin. Gastroenterol. Hepatol. 2017;15:1940\u20131949.e8. doi: 10.1016/j.cgh.2017.04.016.", "ArticleIdList": ["10.1016/j.cgh.2017.04.016", "28419855"]}, {"Citation": "Navarro V.J., Belle S.H., D\u2019Amato M., Adfhal N., Brunt E.M., Fried M.W., Rajender Reddy K., Wahed A.S., Harrison S. Silymarin in Non-Cirrhotics with Non-Alcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo Controlled Trial. PLoS ONE. 2019;14:e0221683. doi: 10.1371/journal.pone.0221683.", "ArticleIdList": ["10.1371/journal.pone.0221683", "PMC6752871", "31536511"]}, {"Citation": "Abbasirad F., Shaygannejad V., Hosseininasab F., Mirmosayyeb O., Mahaki B., Moayedi B., Esmaeil N. Significant Immunomodulatory and Hepatoprotective Impacts of Silymarin in MS Patients: A Double-Blind Placebo-Controlled Clinical Trial. Int. Immunopharmacol. 2021;97:107715. doi: 10.1016/j.intimp.2021.107715.", "ArticleIdList": ["10.1016/j.intimp.2021.107715", "33933848"]}, {"Citation": "Luangchosiri C., Thakkinstian A., Chitphuk S., Stitchantrakul W., Petraksa S., Sobhonslidsuk A. A Double-Blinded Randomized Controlled Trial of Silymarin for the Prevention of Antituberculosis Drug-Induced Liver Injury. BMC Complement. Altern. Med. 2015;15:334. doi: 10.1186/s12906-015-0861-7.", "ArticleIdList": ["10.1186/s12906-015-0861-7", "PMC4580123", "26400476"]}, {"Citation": "Marjani M., Baghaei P., Dizaji M.K., Bayani P.G., Fahimi F., Tabarsi P., Velayati A.A. Evaluation of Hepatoprotective Effect of Silymarin among under Treatment Tuberculosis Patients: A Randomized Clinical Trial. Iran. J. Pharm. Res. 2016;15:247\u2013252. doi: 10.22037/ijpr.2016.1825.", "ArticleIdList": ["10.22037/ijpr.2016.1825", "PMC4986122", "27610165"]}, {"Citation": "Heo E., Kim D.K., Oh S.H., Lee J.K., Park J.H., Chung H.S. Effect of Prophylactic Use of Silymarin on Anti-Tuberculosis Drugs Induced Hepatotoxicity. Tuberc. Respir. Dis. 2017;80:265\u2013269. doi: 10.4046/trd.2017.80.3.265.", "ArticleIdList": ["10.4046/trd.2017.80.3.265", "PMC5526953", "28747959"]}, {"Citation": "Moayedi B., Gharagozloo M., Esmaeil N., Maracy M.R., Hoorfar H., Jalaeikar M. A Randomized Double-Blind, Placebo-Controlled Study of Therapeutic Effects of Silymarin in \u03b2-Thalassemia Major Patients Receiving Desferrioxamine. Eur. J. Haematol. 2013;90:202\u2013209. doi: 10.1111/ejh.12061.", "ArticleIdList": ["10.1111/ejh.12061", "23278124"]}, {"Citation": "Gharagozloo M., Karimi M., Amirghofran Z. Immunomodulatory Effects of Silymarin in Patients with \u03b2-Thalassemia Major. Int. Immunopharmacol. 2013;16:243\u2013247. doi: 10.1016/j.intimp.2013.04.016.", "ArticleIdList": ["10.1016/j.intimp.2013.04.016", "23624215"]}, {"Citation": "Hagag A.A., Elfrargy M.S., Gazar R.A., El-Lateef A.E.A. Therapeutic Value of Combined Therapy with Deferasirox and Silymarin on Iron Overload in Children with Beta Thalassemia. Mediterr. J. Hematol. Infect. Dis. 2013;5:1\u20137. doi: 10.4084/mjhid.2013.065.", "ArticleIdList": ["10.4084/mjhid.2013.065", "PMC3867224", "24363880"]}, {"Citation": "Balouchi S., Gharagozloo M., Esmaeil N., Mirmoghtadaei M., Moayedi B. Serum Levels of TGF\u03b2, IL-10, IL-17, and IL-23 Cytokines in \u03b2-Thalassemia Major Patients: The Impact of Silymarin Therapy. Immunopharmacol. Immunotoxicol. 2014;36:271\u2013274. doi: 10.3109/08923973.2014.926916.", "ArticleIdList": ["10.3109/08923973.2014.926916", "24945737"]}, {"Citation": "Hagag A., Elfaragy M., Elrifaey S., Abd El-Lateef A. Therapeutic Value of Combined Therapy with Deferiprone and Silymarin as Iron Chelators in Egyptian Children with Beta Thalassemia Major. Infect. Disord.-Drug Targets. 2015;15:189\u2013195. doi: 10.2174/1871526515666150731113305.", "ArticleIdList": ["10.2174/1871526515666150731113305", "26239735"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "7", "Day": "13"}, {"Year": "2022", "Month": "8", "Day": "17"}, {"Year": "2022", "Month": "8", "Day": "18"}, {"Year": "2022", "Month": "8", "Day": "26", "Hour": "1", "Minute": "38"}, {"Year": "2022", "Month": "8", "Day": "27", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "8", "Day": "30", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "8", "Day": "21"}], "PublicationStatus": "epublish", "ArticleIdList": ["36014565", "PMC9414257", "10.3390/molecules27165327", "molecules27165327"]}}], "PubmedBookArticle": []}